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ABSTRACT 
 Severe Type 1 Diabetes Mellitus (T1DM) is known to have several negative effects on 
skeletal muscle mass, a condition known as diabetic myopathy. One of these effects is the 
atrophy of the glycolytic muscle fibers. However, the role of intensity of insulin treatment and 
exercise modality in attenuating this loss in fiber cross-sectional area (CSA) has yet to be 
determined. The purpose of this investigation was to examine the effects of 12 weeks of differing 
intensity of insulin therapy and exercise modality on the CSA of plantaris muscle fibers of STZ-
induced T1DM rats. Fibers were identified by myosin heavy chain (MHC) composition. Rats 
were divided into control sedentary (CS), T1DM-sedentary (DCT - conventional versus DIT- 
intensive insulin therapy, blood glucose 9-15mmol/l and 7-9mmol/l, respectively) and T1DM-
exercised (DRE- resistance, DHE-endurance, DCE-combined training, blood glucose 9-
15mmol/l) groups. Exercises consisted of repeated weighted ladder climbs (50%, 75%, 90%, and 
100% pre-determined max. carrying capacity, 1.1 m, 80°) or treadmill running (27 m/min, 6% 
grade, 1hr) 5 days/week for 12 weeks. DCE animals performed resistance and endurance 
exercise on alternating days. Following 12 weeks, diabetic sedentary (DCT, DIT) and diabetic 
exercised (DRE, DHE, DCE) groups did not differ in body weight (BW) or plantaris whole-
muscle weight, except where DIT BW was significantly greater than DRE (P<0.05). The 
moderate hyperglycemia in DCT did not adversely affect muscle fiber CSA suggesting insulin 
supplementation can protect against muscle fiber atrophy. In fact, intensive supplementation 
(DIT) resulted in larger fast twitch MHC’s than either the control (CS) or conventional diabetic 
(DCT) conditions (P>0.05) or aerobic exercise (DHE) in some instances (all fibers expressing 
fast MHC’s except MHCIIx/IIb and MHCIIb – P>0.05). Surprisingly, DIT exhibited 
iii 
 
significantly larger MHCIIa and fewer hybrid fibers than any other group. MHCI fibers were 
unaffected by either diabetes or exercise, however, exercised animals displayed changes in 
percent fiber composition, including a significant proportion of hybrid fibers. These changes 
suggested a shift in fiber type particularly from MHCIIx to MHCIIa. Resistance exercise, 
whether alone (DRE) or in conjunction with aerobic training (DCE) resulted in significantly 
larger MHCIIx and MHCIIb than CS. Treadmill running (DHE) resulted in less hypertrophy of 
fibers expressing fast MHC than the other exercised groups. These findings indicate that 
conventional insulin therapy is sufficient to maintain muscle mass and fiber CSA, while 
intensive insulin therapy and exercise with conventional insulin therapy induce differential 
changes in fiber percent composition and fiber CSA increases.  
 
 
 
 
 
 
 
Keywords: type 1 diabetes mellitus, diabetic myopathy, skeletal muscle, myosin heavy chain 
insulin, exercise, resistance training, endurance training, muscle fiber cross-sectional area, 
muscle mass  
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CHAPTER 1 
 
1.1 Introduction: Diabetes Mellitus Overview 
 
            Diabetes mellitus is a term used to typically describe two distinct pathophysiological 
states, which although differing in the underlying physiological basis of their dysfunction, have 
in common a condition in which blood glucose levels are elevated (hyperglycemia) due to  
impaired insulin response,  which ultimately leads to microvascular, neurological and 
macrovascular complications 
1,2
 . Over time, these complications often manifest themselves in 
the form of retinopathy, nephropathy, peripheral and autonomic neuropathy, atherosclerotic 
cardiovascular and cerebrovascular disease, and skeletal muscle myopathy 
2–4
. In fact, in the 
United States diabetes mellitus is the leading cause of blindness, end stage renal failure, and non-
traumatic limb amputation, and is also associated with a two-to-seven-fold increase in risk of 
developing cardiovascular and cerebrovascular disease 
5
. Indeed, T1DM is a disease that not 
only carries dire health consequences if proper management measures are neglected, but also 
impacts a vast breadth of individuals globally.  
 Of the complications commonly associated with the disease, diabetic skeletal muscle 
myopathy has historically received less research attention comparatively. However, the role of 
maintaining a healthy skeletal muscle mass across the lifespan, in both healthy and diabetic 
populations, has more recently become an area of intensive investigative efforts 
6–9
. In the 
context of diabetic myopathy, the importance of maintaining healthy skeletal muscle mass and 
function begins in adolescence and is vital in improving overall metabolic control, and 
consequently reducing the progression rate of other complications. The role of exercise and 
physical activity in not only the prevention of chronic disease, but in improving health and the 
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amelioration of various complications associated with diabetes mellitus has been identified as an 
important therapeutic strategy in the management of the disease  
8,10–12
.  As skeletal muscle 
exhibits a truly remarkable capacity to adapt to the various stressors exerted on it by exercise, 
identifying the specific effects of differing modalities of exercise (i.e. aerobic, resistance, 
combined) on skeletal muscle in individuals with diabetes provides a unique opportunity to 
examine the effectiveness of exercise in the prevention and  treatment of myopathy. The aim of 
this chapter is to provide an overview on type 1 diabetes mellitus specifically, describe the 
heterogeneity and plasticity of skeletal muscle fibers, and the pathology and mechanisms 
underlying diabetic myopathy.  
1.2 Classification and Diagnosis Criteria 
 
            Diabetes mellitus diagnoses generally fall into two etiopathogenetic categories: Type 2 
diabetes mellitus (T2DM)  in which elevated fasting blood glucose develops as the result of 
resistance to insulin action, and Type 1 diabetes mellitus (T1DM) in which an autoimmune 
mediated destruction of the pancreatic beta-cells in the Islets of Langerhans results in an absence 
of insulin secretion, and in-turn elevated blood glucose 
13
. Symptoms that commence prior to a 
diagnosis of Type 1 diabetes often include polydipsia, polyuria, weight loss and excessive 
hunger, and are believed to be the result of the insulin secretion deficiency induced 
hyperglycemia 
13,14
.  The diagnosis of T1DM generally involves two measurements of a fasting 
blood glucose level of 7 mmol/L or higher or any blood glucose level over 11 mmol/L, and has 
been expanded to include glycated haemoglobin (HbA1C; a measure of glycemic levels over 3 
months) of 6.5% or greater 
15,16
. One of the primary distinguishing features between T1DM and 
T2DM that has garnered predictive diagnostic consideration in the clinical setting is the presence 
of serological auto-antibodies specific to beta-cell auto-antigens. Over 90% of individuals with 
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T1DM express one or more of the following auto-antibodies in the months or years prior to 
onset: insulin reactive (IAA), glutamic acid decarboxylase (GADA), insulinoma-associated auto-
antigen 2 (IA2A) and zinc transporter 8 (ZnT8A)
17–19
. Of particular concern is the increasing 
number of individuals with T1DM who have developed insulin resistance, the primary pathology 
underlying T2DM 
20
. It has been hypothesized that this may be a result of the intensive insulin 
therapy program (that most individuals with T1DM partake in) driving the increase in average 
body weight of T1DM patients that has been observed in recent decades 
21,22
. 
1.3 Epidemiology 
 
            T1DM represents 5-15% of all diabetes mellitus cases, and it is estimated that there are 
over 33 million individuals with T1DM worldwide, and although uncommon, as noted above, 
individuals can be diagnosed with T1DM and T2DM simultaneously 
14,23
. It has also been 
proposed that 5-15% of adults diagnosed with T2DM may actually have T1DM, due to 
difficulties in discerning between T2DM and T1DM diagnoses, and thus the actual number of 
T1DM cases may be underestimated 
24
.  T1DM has also been referred to as juvenile-onset 
diabetes as it commonly develops during adolescence in genetically susceptible individuals as 
the consequence of an environmental trigger 
14,25,26
. However, it should be noted that although 
the age-specific incidence rate rises in the years between infancy and puberty and then tends to 
decline, nearly 30% of T1DM patients are diagnosed after age 20 
5
.  
            Alarmingly, T1DM incidence rates have been steadily increasing annually on a global 
scale, reported to be as high as by  5.3% , 3.3%, 2.6%  and 2.4% in the United States, Norway, 
Germany and Finland, respectively 
5,14,27–29
 It is also of note to consider that the most substantial 
increases in incidence seem to have been amongst children; in Europe, for example, children 
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under 5 years have experienced the greatest increment 
30
. Based on the current trajectory for 
T1DM incidence trends, the number of children under 5 years of age in Europe is expected to 
double between 2005 and 2020 
27
. Considering the fact that the majority of individuals that are 
diagnosed during childhood will likely face a life-time of erratic fluctuations in glycemic levels 
and in turn an increased risk of developing future complications, the importance of early and 
effective  management is critical  
31
. 
1.4 Complications: 
 
Type 1 diabetes has long been associated with a greater risk of mortality due to 
complications, with estimates ranging from 5 – 10 times greater risk compared to individuals 
without the disease 
23
.  The majority of the complications associated with T1DM are classified as 
either microvascular or macrovascular in etiology. Since the introduction of insulin therapy in 
the management of T1DM, long-term complications such as retinopathy, neuropathy, 
nephropathy and cardiovascular disease have represented the greatest contributors to morbidity 
and mortality 
1
. The systemic nature of the metabolic dysregulation associated with T1DM and 
thus chronic hyperglycemia results in pathological complications that are extensive in range.   As 
such, additional debilitating complications that arise as a consequence of T1DM include 
blindness, end stage renal failure and non-traumatic limb amputation, all of which can contribute 
to a chain of circumstances which accelerate the deterioration of health 
5
.  In 1993, the Diabetes 
Control and Complications Trial provided critical evidence for the role of intensive insulin 
therapy (and thus strict glycemic control) in reducing the progression of these complications, and 
identification of the underlying mechanism of  hyperglycemia-induced damage has provided 
insight into the underlying pathogenesis of macrovascular disease, establishing a basis for the 
goals of T1DM management  
2
.  Despite the benefits of intensive insulin therapy in attenuating 
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the progression of the aforementioned complications, one of the drawbacks of maintaining rigid 
glycemic control is the potential development of insulin resistance, which has been observed in 
T1DM populations 
32
.  
Of the many organs detrimentally affected by T1DM, skeletal muscle has received less 
research attention. Skeletal muscle is the largest metabolically active organ by weight, the body’s 
primary glucose sink, and central to insulin sensitivity and basal metabolic rate and experiences a 
myriad of dysfunctions in response to T1DM collectively known as myopathy 
33,34
.  Diabetic 
myopathy is often clinically defined by lower muscle mass, weakness, a reduced physical and 
regenerative capacity, as well as several other histopathological, hormonal, and metabolic 
abnormalities 
4,33–39
.  Interestingly, pathological alterations such as muscle fiber atrophy and 
mitochondrial morphological abnormalities can occur in recently diagnosed T1DM patients (1 – 
28 weeks duration) prior to the manifestation of diabetic neuropathy, indicating that skeletal 
muscle is acutely sensitive to the T1DM milieu 
34,40
.  When the array of physical and functional 
consequences associated with diabetic myopathy are considered in conjunction with the 
predominance of T1DM manifestation   in adolescence, a significant period of muscle growth 
and development, the importance of addressing diabetic myopathy is quite clear. A more detailed 
discussion of the pathology and potential underlying mechanisms exacerbating diabetic 
myopathy will be presented later in this chapter, after sufficient elucidation of skeletal muscle 
physiology and muscle fiber heterogeneity is provided.  
 
 
1.5 Skeletal Muscle Overview: 
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 Skeletal muscle is a truly remarkable tissue, having occupied a fundamental role in 
human evolution and survival, and continuing to act as a critical determinant of health and 
disease. In humans it represents 40% of total body weight, 50-75% of all body proteins, and 30-
50% of all protein turnover 
41,42
.  Skeletal muscle is essential to locomotion, stability/postural 
maintenance, thermogenesis and whole-body metabolism; the heterogeneous nature of the 
individual muscle cells/fibers also permits muscles to perform a wide variety of tasks spanning 
the spectrum of motor control demands 
33,43,44
.  The impressive variation in muscle fiber 
structural and functional properties is mediated by different amounts and specific kinds of 
proteins (of which there are a multitude of isoforms) which function together to define fiber 
phenotype, and as such enable an exquisite adaptability to physical demands 
42,44
 . In 
Hochachka’s “Muscles as Molecular and Metabolic Machines” the author provides an extensive 
list of specific proteins (albeit only including the minimal requirements), which outline the 
functional and structural muscle fiber components that describe a typical fast glycolytic fiber 
phenotype. As such, the author fixates on the fact that this brief list of components alone would 
require the regulated expression of over 100 genes, and  thus the adaptive plasticity exhibited by 
muscle fibers is theoretically only limited by the number of ways in which the contributing 
isoforms are assembled 
42
.  
 Human skeletal muscle displays a remarkable capacity to adapt to the physiological 
stresses imposed on it by physical activity and exercise demands. For example, an examination 
of the vastus lateralis skeletal muscle properties of a world-champion sprint runner revealed a 
high abundance of pure MHC IIX fibers (24%) that were highly transcriptionally responsive to 
high intensity exercise, and a total glycolytic fiber population of 71% ; the power output of 
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which were higher than any reported human values to date 
45
.  Conversely, as East African black 
athletes have long been regarded as dominant in endurance athletic events, investigation of 
vastus lateralis muscle biopsies of Xhosa compared to Caucasian endurance athletes (matched 
for training and racing distances) revealed that Xhosa runners exhibited lower plasma lactate 
concentrations at 80% Peak Treadmill Speed (PTS) and significantly higher percentage 
composition MHC IIa and lower MHC I compared to Caucasian runners, although oxidative 
enzyme activities did not differ 
46
.  The skeletal muscle phenotypic adaptations found in humans 
occur along a broad spectrum and are implicated in not only athletic performance, but play a 
significant role in the maintenance of health across the life span.  
1.6 Fiber Type Nomenclature and Classification: 
 
 The process in which the heterogeneous properties of skeletal muscle fibers have been 
elucidated and classified has been gradual, mirroring advancements in available scientific 
techniques capable of investigating the differing functional, metabolic, and structural properties. 
As such, the nomenclature has evolved accordingly, in order to appropriately catalogue these 
findings and incorporating more information in each definition. Spangenburg and Booth provide 
a description of this process, beginning as early as 1873 when Ranvier distinguished “red” 
muscles that contracted slowly from “white” muscle that contracted fast 47. In the 1960’s these 
muscles/fibers (type I and II) were further classified by their contractile properties as well as 
their oxidative capacity, introducing a new sub-classification of type IIA and type IIB 
48,49
. The 
refinement of analyses of metabolic properties of muscle fibers through microdissection of single 
fibers also allowed the identification of widely varied enzyme activities between fiber types 
50–52
. 
In the 1980’s, the use of electrophoretic separation techniques allowed correlation between MHC 
composition, contraction speed and myosin ATPase to be identified 
53,54
. The MHC composition 
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based classification of muscle fibers was furthered expanded with the identification of a third 
unique MHC, MHC IIx/d 
55–57
. The subsequent improvements in immunohistochemical 
techniques and comparison with histochemical myosin ATPase fiber typing permitted the 
observation of human fibers histochemically staining positive for type IIB myosin ATPase to 
actually expressing MHC IIx/d, and as such delineating a complete lack of MHC IIb in human  
muscle 
58
. One of the more recent observations of importance to the MHC centered approach to 
fiber phenotype nomenclature was the identification of fibers displaying heterogeneous MHC 
composition; hybrid muscle fibers 
59,60
.  Although not all muscle proteins associated with 
specific MHCs are necessarily expressed in parallel, the central role of myosin as the molecular 
motor and the differing MHC composition  across fiber types suggest MHC expression as the 
best available marker for fiber typing and communication purposes 
44,47
. Thus, according to the 
MHC based classification and nomenclature of fiber types, fiber phenotype appears to occur 
along a spectrum that could be described as MHC I MHC IIa  MHC IIx/d  MHC 
IIb with hybrid MHC co-expression occurring “between” pure MHC fibers. This MHC 
expression sequence is not requisite however; fibers co-expressing MHC I and IIx while lacking 
MHC IIa have been identified 
44,61
.  
1.7 Skeletal Muscle Fiber Diversity: 
 
 The diverse nature of the functional, structural, metabolic, and adaptive properties of 
muscles fibers is essential to the ability of skeletal muscles to perform tasks of varying physical 
demands. Phenotypic changes in response to neural and hormonal influences involve a myriad of 
different molecular mechanisms responsible for mediating the activation of specific gene 
programs, and in turn, specific isoform expression 
44,47,62
.  The significant role of muscle activity 
in the prevention and amelioration of chronic disease and complications suggests the importance 
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of further investigation in elucidating activity (and inactivity) dependent signaling pathways in 
order to identify potential therapeutic targets 
44
.  As mentioned previously, MHC IIb is only 
expressed in some mammals (i.e. mice, rats etc.). The complete absence of MHC IIb fibers in 
human skeletal muscle is likely the consequence of body size’s role in functional demands, 
where the energy metabolism for unit body mass is inversely related to body size (Kleiber’s law) 
and basal metabolic rate (BMR) per unit mass varying with three-fourth power of body mass 
44,63
. The thickness (diameter) of individual muscle fibers also appears to scale allometrically; 
although surprisingly human cyclists have been shown to possess significantly larger vastus 
lateralis fibers than those obtained from a single lion (Panthera leo) specimen, indicating 
exceptions to this observation exist 
64
.  Additionally, the maximum shortening velocity of each 
fiber type appears inversely allometrically scaled, although this relationship is not fixed as horse 
type I and IIa fibers maintain greater shortening velocities than humans despite significant body 
mass disparity 
44,65,66
.   
1.8 Effective Motor Neuron – Muscle Fiber Coupling… the Motor Unit: 
 
 As the primary function of fiber heterogeneity can be simplified to a necessity of 
coupling specific isoforms in such a way that the physical requirements stipulated of a muscle 
can be achieved efficiently, one of the most basic pairings is that of a motor neuron with 
appropriate fiber constituents. Efficiently matching fiber phenotypes with specific neural activity 
patterns is an essential aspect of utilizing the distinct properties of different fiber types and plays 
a primary role in fiber remodeling in adult skeletal muscle 
44
.  As such, the neuromuscular 
system is organized into discrete units (motor units) consisting of a motor neuron and the 
homogeneous muscle fiber population it innervates 
67
. In 1985 Henneman proposed the “size 
principle” which theorized the orderly recruitment of motor units based on nerve cell size, where 
10 
 
 
slow twitch motor units are recruited before larger fast twitch units 
68
. The activation of motor 
units of increasing size is critical to the performance of fine motor skills, and therefore muscles 
in the human hand /forearm tend (abductor pollicis longus) to contain a high number of motor 
units despite a smaller absolute size comparatively, as determined by motor unit number 
estimation (MUNE). As one of the health consequences of T1DM is neuropathy, MUNE has 
been recommended as a measure to predict motor unit dysfunction in animals, and MUNE has 
even been found to be lower in children with T1DM 
69,70
.  
1.9 Myosin Isoform Contractile Properties: 
 
 The myosin isoforms present in skeletal muscle are the primary determinants of fiber 
contractile properties, ATP consumption, and the fiber’s ability to respond to the neural demands 
imposed on it. In accordance with the diversity of motor unit activity patterns, the contractile 
performance and ATP consumption requirements of the different myosin isoforms occur across a 
spectrum. The mechanical power generated by muscle fibers defined in terms of power is 
characterized by the mechanical energy generated per unit of time, and as such is directly related 
to the chemical energy released by ATP hydrolysis via myosin ATPase 
44
. Peak power output 
values increase from slow MHC type I fibers to IIb fibers, which possess the highest peak power 
values of all mammalian species; indeed, this range across fibers can be as high as 10 fold when 
measured in vitro at low temperatures 
44,71
.  
 Mechanical power generation is determined by the interaction of the maximum isometric 
force (Po) and the maximum unloaded velocity (Vmax), and the curvature describing this 
relationship (a/Po) essentially describes the force sustained at a particular velocity 
44
.  As such, 
these parameters determining power output display differences between fiber phenotypes. The 
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Vmax of muscle fibers are determined exclusively by myosin isoform, and show a pattern of 
increasing velocity from slow fibers to fast fibers, with IIb fibers exhibiting the highest 
maximum velocity 
64,72,73
. In fact, the higher overall proportion of pure MHC IIx fibers that have 
been observed in world champion human sprinters and the fastest terrestrial species on earth, the 
cheetah (Acinonyx jubatus), provide excellent examples for the superior speed of contraction 
parameters bestowed by these fiber phenotypes 
45,74,75
. Maximum isometric force and specific 
force is also higher in fast compared to slow fibers and this disparity has been suggested to be the 
result of a greater number of strongly bound myosin heads compounded by greater force 
production per head, comparatively 
64,76–78
.  Thus appropriately, studies examining MHC isoform 
content in the vastus lateralis muscle homogenates of body builders have reported higher 
proportion (~15%) of IIx isoform compared to active young men (~5%) 
79
. However, it should be 
noted that inferences made from muscle homogenates with the regular occurrence of hybrid 
fibers co-expressing MHC isoforms, an assumption of a greater number of pure IIx fibers is 
inappropriate unless detected at the single fiber level 
75
.  
The myosin-ATPase activity levels of the different MHC isoforms also show marked 
variation in rate of energy release and consumption, and thus contribute to the contractile 
properties of muscle fibers. During isometric contraction in vitro, steady-state ATPase activity 
has revealed that ATP hydrolysis rate also increases across the spectrum of fiber types, with IIb 
fibers possessing the highest rate  
80–82
.  However, the amount of ATP consumed per unit time 
per unit tension (tension cost) is lower in slow fibers, thus contributing to their role in 
maintaining repetitive contractions and posture 
80
. Taken together, these functional parameters 
support the role of different MHC fiber types being expressed in response to specific neural 
activity patterns while permitting a wide range of dynamic movements.  
12 
 
 
1.10 Metabolic Control: 
 
The supply and regeneration of ATP during muscle activity is achieved through complex 
metabolic regulation involving the integration of several different biochemical pathways. Indeed, 
ATP hydrolysis provides the basis of all cellular energy supply, with 1 mol of ATP providing 
~50-60 kJ energy, and during muscle contraction over 70% of ATP consumption is related to 
myosin ATPase activity and the remaining 30% ionic transport 
83,84
. These pathways involve 
different metabolic substrates and are most simply differentiated as anaerobic (O2-independent) 
or aerobic (O2-dependent), and their relative utilization and efficiency of energy production 
shows marked variation between fiber types in response to their respective contractile and 
functional properties.  ATP is generated anaerobically primarily through the phosphagen system 
substrate creatine phosphate (PCr) and through anaerobic glycolysis/glycogenolysis, which 
partially catabolizes glucose to rapidly supply energy while transitioning from rest and in the 
early stages of physical activity. Conversely, aerobic generation of ATP is maintained by aerobic 
glycolysis and mitochondrial oxidation of both glucose and free fatty acids, the complete 
catabolism of which enables huge increases in yield of ATP/mol  of substrate and a greater 
capacity for sustained energy production 
42
. The delay in activation of aerobic metabolic systems 
compared to the immediate reliance of anaerobic PCr and subsequently anaerobic glycolysis is 
termed “metabolic inertia”, and this appears to be a pattern in which a decline in anaerobic ATP 
production/capacity is matched with an inversely parallel increase in oxidative mitochondrial 
ATP generation 
85
. It has been suggested that in exercise conditions in vivo in humans, the 
limitations of the “cardiac pump” and thus O2 delivery to muscle mitochondria is a major 
determinant of the activation of aerobic metabolic control 
42,86
.  In accordance with the 
impressive heterogeneity displayed in the mechanisms underlying neural activity patterns, 
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sarcolemmal excitability, EC coupling and myosin contractile properties, fiber types display 
pronounced differences across a continuous metabolic spectrum.   
The different MHC fiber types exhibit considerable variation in fiber size and thickness, 
generally following a trend of increasing cross-sectional area from type I fibers being the 
smallest to the robust IIx and IIb fibers. This increase in fiber size is inversely related to the 
expression of the oxidative enzyme succinate dehydrogenase (SDH) and positively correlated 
with the glycolytic enzyme α-glycerophosphate dehydrogenase (GPD) 87. The reliance of smaller 
fibers on primarily oxidative means of ATP generation is further supported by the presence of an 
increased absolute number and ratio of capillaries to fibers, as well as an increased relative 
proportion of mitochondrial volume (6%, 4.5% and 2.3% in MHC I, IIa, IIx respectively) 
88,89
. 
Additionally, the mitochondria of slow oxidative fibers also exhibit morphological differences in 
the form of densely packed cristae 
90
. From an enzymatic perspective, citric acid cycle (TCA) 
enzyme activities (essential to aerobic metabolism) are over twice as high in slow fibers 
compared to fast fibers in rabbit muscle 
91
. The fundamental involvement of aerobic metabolism 
in sustaining muscle activity during repetitive contractions is further complemented by increased 
glucose uptake capacity, GLUT4 (glucose transporter) protein expression, and myoglobin 
content in slow compared to fast fibers 
92–94
. Interestingly, myoglobin is nearly absent in IIb 
fibers, and in humans oxidative fibers exhibit ~50% higher content than fast glycolytic fibers 
94,95.  In terms of mitochondrial oxidation, FFA’s contribution to TCA is also higher in slow 
fibers compared to fast fibers, and slow fibers have also shown greater O2 consumption when 
maximally stimulated (0.048 mM/s and 0.022mM/s in soleus and gastrocnemius, respectively) 
96
. 
 The larger, glycolytic fibers exhibit enzymatic and metabolic properties that contrast 
those of the smaller, oxidative fibers. The function of anaerobic metabolism in rapidly producing 
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energy is apparent when comparing the glycolytic power output ; during short duration, intense 
activity in vivo in humans fast fibers consume 2.5 mM/s of ATP compared to 1.2 mM/s in slow 
fibers 
97
. This rapid anaerobic glycolytic production of energy is aided by the fact that at rest, fast 
fibers display slightly higher PCr content as well as much higher glycogen content 
42,97,98
. 
Interestingly, the amount of PCr available for use as metabolic substrate appears to be more 
dependent on fiber hypertrophy and not adjustments in concentration; this finding corresponds 
with the greater potential for hypertrophy of MHC type II glycolytic fibers 
99
. In terms of 
activation time-course, Bangsbo et al. demonstrated the initial reliance on PCr metabolism 
followed by gradual increases in anaerobic and finally aerobic glycolytic and mitochondrial 
metabolism in healthy human subjects, with PCr supplying 80% of power output for initial 30s, 
45% for 60-90s, and ~30% at 120s onwards 
85
. Similar to PCr metabolism, anaerobic glycolysis 
is capable of producing high rates of power output and heavily relied upon by fast fibers 
97
.  
Indeed, all of the enzymes involved in glycolytic metabolism, including the rate-limiting 
phosphofructokinase (PFK) show much higher activity levels in fast compared to slow fibers 
51,52
.  The sympathetic nervous system stimulated hormonal release of epinephrine also displays a 
greater effect on glycogen breakdown in fast fibers, likely indicative of epinephrine’s role in the 
“fight-or-flight” response necessitating rapidly available energy 100. As would be expected, the 
varied metabolic properties of specific fiber types results in a range of energy consumption 
demands during maximal isometric contraction in humans 
101
. As such, MHC type I fibers have 
been found to consume 6.5 mmol/kg/s, while IIa and IIx fibers have been measured consuming 
17.6 mmol/kg/s and 26.6 mmol/kg/s, respectively 
44,102
. 
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1.11 Satellite Cells, Growth, Regeneration and Fiber Type: 
 
 A unique feature of skeletal muscle is the post-mitotic, multi-nucleated nature of 
individual muscle fibers. As a result of this terminal differentiation state, the capacity for growth 
(hypertrophy) and regeneration exhibited by muscle fibers is largely due to the presence of a 
small population of progenitor cells found between the basal lamina and sarcolemma, known as 
satellite cells 
103–108
. First identified in 1961, satellite cells (SC) normally exist in a quiescent 
state, but in response to a number of different stimuli these cells become activated, proliferate, 
and fuse to existing fibers becoming new myonuclei 
106
. A number of molecular markers 
differentially expressed by SC’s  have been identified, and include but are not limited to: Pax 7, 
Pax 3, MyoD, Myf5, NCAM/CD-56; however, myogenic regulatory factors such as MyoD and 
Myf5 are not expressed by quiescent SC 
108,109
. In terms of SC activation and signaling, a number 
of contributing mechanisms have been proposed, all of which have been described as 
contributing to the specific “niche” in which SC exist outside of the muscle fiber 108. Factors that 
have been identified to contribute to the maintenance of this specific niche and SC activation 
include the extracellular matrix (ECM), vascular and neural networks, myofiber secreted factors, 
mechanical tension, Wnt and Notch signaling, and hormones such as IGF-1 
108,110–123
. Although 
the exact mechanisms and interactions of these niche components is beyond the scope of this 
review, the topic has been reviewed extensively elsewhere 
106–108
. In fiber hypertrophy, the 
contribution of SC to the existing myonuclei pool is believed to be driven by increases in fiber 
cytoplasm, as myonuclei are unable to divide, and the nuclei to cytoplasm ratio or “myonuclear 
domain” appears to be constant in adult fibers. Furthermore, SC have been shown to play a 
critical role in fiber regeneration in response to exercise and myotrauma, where ablation of 
Pax7+ SC abolishes the regeneration capacity in adult muscle 
124–126
. Physical exercise such as 
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resistance training has also been shown to be highly effective at increasing the density and 
activation of satellite cells, as determined by immunohistochemistry and electron microscopy 
109,127–130
. 
 SC content appears to vary based on muscle fiber type, with slow fibers generally 
possessing a greater number of SC’s than fast fibers and potentially maintaining intrinsically 
different properties based on fiber type of origin 
109,131–133
. For example, the percentage of 
satellite cells in the soleus has been found to be two to four times higher than that of the EDL 
and tibialis anterior (TA) muscles, composed predominately of slow and fast twitch fibers, 
respectively. Interestingly, SC content in sedentary elderly compared to young individuals has 
been shown to be reduced in fast fibers specifically, and comparatively elderly subjects tend to 
experience reduced increases in SC density in response to resistance training 
107,134–136
.  This 
fiber-type specific SC dysfunction does not appear to be exclusive to aged individuals; satellite 
cell abnormalities have also been observed in models of diabetes, in which fast fibers are the 
most susceptible to diabetic myopathy 
137
.  For example, in steptozotocin (STZ) rodent models of 
T1DM, SC activation has been found to be greatly reduced,  and  overall regeneration capacity 
attenuated following myotrauma, as well as SC exhibiting reduced MRF expression and 
impaired differentiation 
137–141
.  Although the combined effects of oxidative stress, a chronic 
low-grade inflammatory profile, and impaired ECM remodeling as a result of the diabetic milieu 
have been suggested to contribute to these dysfunctions, the T1DM specific expression of 
plasminogen activator inhibitor-1 (PAI-1) and myostatin (MSTN) are particularly interesting 
137
.  
MSTN is a known negative regulator of muscle mass and a strong repressor of satellite cell 
activation which shows elevated protein and gene expression in T1DM  
142–146
 . PAI-1 is a 
hormone involved in the regeneration process and ECM turnover rate, impedes fiber recovery 
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following injury, contributes to SC regulation and is found to be elevated in STZ diabetic rats 
34,141,147–151
. Although both of these regulatory mechanisms contribute to diabetic SC dysfunction 
independently, the positive correlation between glucocorticoid levels (which are elevated in 
diabetic myopathy), PAI-1 expression and MSTN gene expression would seem to indicate an 
inter-related SC dysfunction pathogenesis 
34,147,148,152,153
.  Furthermore, the fast fiber specific 
atrophy in both diabetic and aged populations with the presence of SC abnormalities could also 
suggest some overlap in the pathogenesis of the two atrophic states, providing further impetus 
for additional fiber specific myopathy and sarcopenia research investigation.  
1.12 Diabetic Skeletal Muscle Myopathy Characterization: 
 
 As stated previously, diabetic myopathy is a condition typically characterized by reduced 
muscle mass, muscular weakness, diminished physical work capacity and decreased maximal 
force production 
4,34,36,37,154
.  Furthermore, the reduced muscle mass and force production that 
manifest in diabetic myopathy seem to be related to muscle fiber atrophy, with fast glycolytic 
fibers (MHC IIx, IIb) appearing to be the most severely affected whereas slow fibers are 
relatively unaffected  
33,34,155–159
. Additionally, children with T1DM have also been found to have 
reduced motor unit number estimates (MUNE) compared to non-diabetic children, indicating the 
possible role of neuropathy in diabetic myopathy progression 
70
. However, recently diagnosed (1 
to 28 weeks) T1DM patients have also been shown to exhibit fiber atrophy, Z-disk disruptions 
and mitochondrial abnormalities prior to the onset of any neuropathy, indicating that skeletal 
muscle is acutely and detrimentally sensitive to the diabetic milieu 
34,40,160
. In addition to these 
complications, diabetic myopathy reduces the regenerative capacity of muscle fibers, with 
elevated levels of MSTN and PAI-1 negatively impacting SC activation and recruitment 
141,145
. 
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As such, it is quite apparent that diabetic myopathy embodies a myriad of dysfunctions that 
collectively contribute to functional and physiological consequences.  
Although diabetic myopathy has historically not received the same level of research 
attention as other complications associated with T1DM, maintaining a healthy level and quality 
of muscle mass is central to the maintenance of overall physical health. As skeletal muscle is 
responsible for enabling locomotion, as well as serving as the primary glucose sink and 
metabolic regulator, investigating the underlying pathological mechanisms and determining 
intervention strategies such as specific exercise modalities is crucial to attenuating the 
progression of complications related to diabetic myopathy 
33,34
. As T1DM is most often 
diagnosed in children and adolescents, and skeletal muscle undergoes significant development 
and growth during childhood and puberty, early intervention in preventing the onset of the 
dysfunctions associated with diabetic myopathy is of critical importance 
34
.  The findings of 
several studies investigating the physical work capacity of adolescents and adults with T1DM are 
somewhat challenging, as many studies have indeed shown reduced capacities compared to non-
diabetic cohorts, while other studies have reported no apparent physical impairment in 
performance 
34,161–165
 Additionally, some of the studies in which reduced submaximal and 
maximal workload were observed found that the degree of capacity detriment corresponded  
inversely to metabolic control (HbA1c), introducing question as to whether poor metabolic 
control is the result or the cause of this reduced  physical capacity 
34,161,162
. In fact and somewhat 
surprisingly, some human T1DM studies have even reported an increase in the relative percent 
composition of fast fibers, as well as an increase in glycolytic enzymes 
34,38,39
. It should be noted 
that these findings could be the result of the individuals in these studies maintaining excellent 
glycemic control and insulin therapy management 
34
.  Further complicating this, the use of 
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functional measures such as VO2 max and PWC170 (submaximal exercise) do not necessarily 
indicate muscle and fiber specific dysfunctions, as such measures involve the interaction of both 
the cardiovascular and skeletal muscle systems 
34
.  
The use of animal models such as the alloxan, STZ or Ins2
Akita+-
 diabetic mice and  rats 
have provided a wealth of information regarding the impact of diabetic myopathy on whole 
skeletal muscle and individual fibers. For example, a study comparing the STZ and Ins2
Akita+/-
 
diabetic mice models to control animals after 8 weeks of diabetes found significantly reduced 
gastrocnemius-plantaris-soleus mass (control 0.16 +- 0.005g, Ins2
Akita+/- 
0.12 +- 0.003g, STZ 
0.12 +- 0.01g) and IIB/D fiber size (control 2241 +- 144 µm
2
, Ins2
Akita+/-
 1294 +- 94 µm
2
, STZ 
1768 +- 163 µm
2
) in the diabetic animals compared to controls 
166
. STZ rodents have also shown 
muscle specific loss in force, where soleus or slow fibers show no loss in force and EDL or fast 
fibers show impaired force production 
155,156,167
. Another study using a 90% partial 
pancreatecomy rat model of diabetes found  that after 8 weeks of diabetes both type I and II 
fibers occupied ~25% and ~45% less area, respectively, as well as diabetic animals exhibiting 
45% lower gastrocnemius-plantaris-soleus complex mass and significantly lower absolute force 
production 
168
.  Surprisingly, some studies have actually reported increases in relative force 
production  
34,169,170
.  This finding may seem antithetical when compared to other studies, Krause 
et al. have postulated that this finding may be caused by altered Ca
2+
 transients in the fibers, as 
STZ rats have been shown to exhibit hyperactive Ca
2+
 kinetics and SERCA activity 
34,171 
Although a number of other animal studies display findings similar to these, the differential 
severity of atrophy and loss of force production could be a result of the duration of diabetes, 
different experimental glycemic ranges due to the presence or absence of insulin, or even the 
dosage of diabetes-inducing compounds like STZ administered. For example, the addition of 
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various doses of STZ (0.25 – 3.0 mg/ml of a glucose-analogue used to induce pancreatic beta-
call destruction) to myoblasts in vitro was found to show that both chronic and acute exposure 
resulted in reduced proliferative capacity in a dose- dependent manner, implicating STZ in fiber 
dysfunction independent of systemic hyperglycemia 
172
. Furthermore, studies investigating the 
effect of different dosages of STZ (60 mg/kg, 80 mg/kg, 100 mg/kg and 150 mg/kg) found 
alterations in metabolic enzymes in higher dosage groups, and rats administered lower doses 
responded better to insulin treatment 
173
. As such, some researchers have adopted lower 
concentration, multi-dose STZ administration  methods in an attempt to avoid complications 
resulting from STZ independent of beta-cell destruction 
174,175
.  Another issue amongst studies 
using rodent models of diabetes is the fact in many cases the secretion or administration of 
exogenous insulin is absent, and as a result these animals often have extremely high blood 
glucose levels for extended periods of time, likely further exacerbating muscle myopathy and 
making translation to human muscle difficult.   
1.13 Pathological Contributors and Underlying Mechanisms: 
 
 Although the underlying mechanisms believed to primarily contribute to the atrophy and 
reduced force production observed in cases of diabetic myopathy are hyperglycemia and an 
abnormal protein synthesis-degradation balance, a number of additional pathological contributors 
have also been identified  
33,34
. For example, the metabolic hormones adiponectin and leptin may 
not directly contribute to muscle fiber atrophy per se, but the metabolic effects of their abnormal 
expression patterns in T1DM may contribute to diabetic myopathy. Adiponectin and leptin are 
adipokine hormones that are known to increase insulin sensitivity and fat metabolism, and have 
been found to be increasingly and decreasingly expressed, respectively, in individuals with 
T1DM 
33
. Although leptin levels may be decreased in individuals with poorly controlled T1DM, 
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insulin therapy has been shown to recover leptin expression in children and STZ rats 
33,176,177
. 
Interestingly, the elevated expression of adiponectin found in individuals with T1DM appears to 
arise independent of glycemic control, and has been shown to be positively correlated with 
intramyocellular lipid (IMCL) accumulation  in the skeletal muscle fibers of non-diabetic mice 
20,33,178,179
.  Higher levels of IMCL have also been observed in the skeletal muscle of humans 
with T1DM and STZ rodents, and  have been suggested as contributing to altered insulin 
sensitivity 
20,166,180
. Coleman et al. have theorized that increased IMCL content associated with 
elevated adiponectin expression in T1DM could be the result of a metabolic compensatory 
mechanism in which lipids are removed from the circulation and stored within muscle fibers 
33
. 
 Similar to other T1DM complications such as vascular disease and neuropathy, 
hyperglycemia resulting from a lack of pulsatile insulin release is considered a primary 
pathological mechanism in diabetic myopathy. Hyperglycemia resulting from T1DM accelerates 
the process of glycation, which occurs normally with aging, and results in the formation of cross-
linkages between proteins known as advanced glycation end products (AGE) 
181,182
. AGE 
accumulation in both serum and muscle has been established as contributing to diabetic 
complications, and has even been associated with reducing motor function and grip strength in 
non-diabetic elderly individuals 
2,181,183–186
. In T1DM muscle, AGE accumulation appears to 
occur primarily in fast fibers, but increases in the AGE content of muscle fiber SERCA pumps 
has also been reported 
183,187,188
. In essence, increased AGE content in myofibrillar protein 
represents a post-translational modification in which myosin structure and function is negatively 
affected; for example, glycation has been shown to reduce in vitro myosin motility and modify 
molecules in the ECM 
2,189
.  
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 Hyperglycemia also promotes the activation of the polyol pathway, in which the enzyme 
aldose reductase (AR) inadvertently depletes NADPH through the reduction of excess glucose to 
sorbitol, and in turn reduces the regeneration capacity of the intracellular anti-oxidant glutathione 
2
. As such, chronically elevated levels of reactive oxygen species (ROS) and oxidative stress 
develops and is believed to contribute to the diabetic myopathic condition 
34,190
. Support for this 
concept is provided by the findings that the use of aldose reductase inhibitors (ARI) have been 
shown to ameliorate contractile function and muscle fiber area in STZ diabetic rats 
34,191,192
. In 
terms of the preferential atrophy of fast fibers, fast fibers have been reported to exhibit a high 
degree of mitochondrial free radical leak, and  the reduction in anti-oxidant defense due to polyol 
pathway activation could be considered to contribute to this atrophy 
193
.  In fact, a study 
investigating the fiber-specific responses to cachectic stimuli found that mice injected with 
lipopolysaccharide endotoxin displayed  muscle/fiber type specific responses; the fast vastus 
lateralis muscle expressed  significantly higher levels of ROS and E3 ubiquitin ligases atrogin-1 
and muscle ring finger-1 (MuRF1) compared to the slow soleus muscle 
194
.  Conversely, the slow 
soleus muscle was found to express enhanced nitric oxide (NO), inducible NO synthase (iNOS) 
and antioxidant genes in response to the oxidative stress “insult”, which the researchers 
suggested could be a mechanism by which slow fibers display resistance to oxidative stress 
induced atrophy 
194
. The E3 ubiquitin ligases atrogin-1 and MuRF1 have been identified as 
playing an important role in skeletal muscle atrophy, and have been reported to be inactivated by 
IGF-1, which happens to be reduced in adolescents and adults with T1DM 
195–201
. In addition to 
increased atrogene expression, 21 days of STZ diabetes in rats has been reported to reduce 
expression of MRF’s myogenin, MyoD and Jun D concomitantly with decreases in antioxidant 
levels and synthesis of CK and myosin light and heavy chains 
139
. Indeed, the administration of 
23 
 
 
the steroid hormone dehydroepiandrosterone (DHEA) and subsequent amelioration of MRF and 
antioxidant expression, as well as protein synthesis, has been suggested by the authors to support 
the atrophic role of oxidative stress in STZ diabetes 
139
. 
 The dynamic nature of muscle mass, undergoing frequent fluctuations of both protein 
synthesis and degradation activity, suggests that an imbalance in protein anabolism and 
catabolism likely contributes to the diabetic myopathy state. Indeed, the presence or absence of 
insulin has a substantial effect on the balance between protein synthesis and proteolysis in T1DM 
muscle 
202–204
. However, most evidence supports the notion of insulin playing a role in inhibiting 
proteolysis instead of actually increasing protein synthesis in TIDM 
34,205,206
. This matter is 
somewhat complicated by reports in which insulin has been shown to stimulate increased rate of 
protein synthesis in STZ diabetic rats, but not in human adults and adolescents with T1DM 
207–
209
. However, in cultured C2C12 myotubes, the addition of insulin and IGF-1 have been shown 
to increase protein synthesis by 62% and 35%, respectively, although these results would seem to 
indicate some inherent difference between insulin action in vivo versus in vitro models 
210
. 
Accordingly, the aforementioned researchers indicated that insulin and IGF-1 both acted to 
stimulate the phosphorylation/activation of the phosphatidylinositol-3 kinase (PI3K) – Akt – 
mammalian target of rapamycin (mTOR) pathway, a signaling pathway strongly associated with 
muscle growth and hypertrophy 
195,210
. The activation of the PI-3 K signaling pathway by insulin 
acts to inhibit the ubiquitin-ligase atrogin-1, in turn negatively regulating the expression of 
ubiquitin and thus the proteolytic ubiquitin-proteasome (Ub-P) pathway 
206,211
. Furthermore, the 
fact that components of the Ub-P proteolytic pathway are often found to be upregulated in 
T1DM corresponds with the atrophic condition commonly observed in diabetic myopathy 
34,139,206,212,213
. Interestingly, Akt expression and activation in STZ rats has been found to be 
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lower in fast muscles, but not in slow muscles compared to controls, and thus may indicate 
another aspect of the fiber specific atrophy in diabetic myopathy 
34,214
.  The infusion of human 
recombinant IGF-1 in STZ rats has also been shown to partially restore growth rate in diabetic 
growth-arrested rats, and further addition of insulin resulted in completely restored growth 
34,215
. 
As IGF-1 and insulin are structural homologues which act through similar receptors, increasing 
IGF-1 content local/autocrine to skeletal muscle through interventions such as resistance exercise 
could provide promising results for diabetic myopathy
216,217
. In a model of diabetes in which rats 
were partially pancreatectomized (~90%) and subjected to 8 weeks of progressive resistance 
training, exercise was found to increase soleus and gastrocnemius-plantaris complex wet weight 
compared to sedentary rats and  partially restored IGF-1 concentration 
204,218
. Interestingly, the 
same increases in IGF-1 concentration in the non-diabetic acutely exercised animals was not 
observed, and the authors of these studies suggest that the increase in circulating IGF-1 in 
diabetic rats may act in a compensatory manner 
218
. 
1.14 Role of Exercise in T1DM Management: 
 
Engaging in regular physical activity and exercise is an important component of the 
health regimen in T1DM, and is associated with an increased life expectancy and reduced risk of 
developing complications, and even an inversely proportional relationship to mortality risk 
11,219–
222
. Some of the additional health benefits that exercise confers to individuals with T1DM 
include (but are not limited to) improved cardiorespiratory and vascular health, decreased insulin 
requirements, improved endothelial function and overall quality of life 
220,223,224
. Despite these 
established benefits, it has been reported over 60% of adults with T1DM do not partake in the 
recommended levels of physical activity, and due to a scarcity of specific research in the area, 
the appropriate type, duration, frequency and intensity of physical activity necessary to induce 
25 
 
 
glycemic improvements still remains somewhat unclear 
219,220,225
.  A contributing factor to the 
poor adherence to a therapeutic physical activity routine in individuals with T1DM is the fear of 
post-exercise induced and late-onset (nocturnal) hypoglycemia 
226,227
. Interestingly, contrary to 
the known risk of post-exercise hypoglycemia in moderate-intensity aerobic exercise, it has been 
observed that anaerobic exercise (such as resistance training) can actually induce post-exercise  
hyperglycemia, further highlighting the benefits of characterizing the divergent effects of 
differing exercise modalities in T1DM 
228
. It follows that the focus of a large number of exercise 
interventions in T1DM patients has typically been on improving glycemic control measuring 
markers like glycated hemoglobin (HbA1c) or fructosamine in order to reduce the risk of 
cardiovascular disease and related complications 
219,228
. Although these studies do not necessarily 
examine the effects of exercise on skeletal muscle mass and fiber size specifically, improving 
glycemic control through exercise and thus restoring euglycemia could confer improvements in 
muscle mass in T1DM patients.  
In terms of preventing diabetic myopathy, or maintaining/ improving muscle mass with 
exercise in T1DM patients, research investigating the effects of different modes of exercise on 
skeletal muscle/fiber size is somewhat sparse. The molecular and physiological effects of 
progressive resistance training on skeletal muscle and the corresponding strength gains and 
muscle hypertrophy that occurs in response has been studied extensively in healthy humans and 
rodents, and has shown promise in attenuating the deleterious effects of diabetic myopathy 
229–
231
. In one rodent study, partially pancreatomized (~90%) diabetic rats subjected to 8 weeks of 
progressive overload resistance training were shown to exhibit significant soleus and 
gastrocnemius-plantaris muscle hypertrophy despite diabetes resulting in lower muscle wet 
weight compared to healthy animals 
232
.  Another study using STZ-induced T1DM rats 
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performing a 1 meter weighted-ladder climb progressive resistance training protocol for 5 weeks 
(5 sets of 4 repetitions/climbs) resulted in significant hypertrophy of the flexor hallucis longus 
(FHL) muscle as determined by increased FHL weight-to-body weight in trained versus 
untrained animals 
233
 In a human study investigating progressive resistance training in Hispanic 
older adults with T2DM, 16 weeks of resistance training (3 times per week, 3 sets of 8 
repetitions) was found to significantly increase mean upper and lower body strength, whole-body 
lean mass, muscle quality (strength per unit volume of muscle) and the CSA of type I and type II 
muscle fibers (vastus lateralis) 
234. It appears that despite the diabetic milieu’s propensity for 
decreasing muscle mass, resistance training is still capable of eliciting skeletal muscle 
hypertrophy; however, closer examination of the MHC fiber-specific responses to resistance 
training in T1DM is still warranted in order to better characterize the differential responses of the 
heterogeneous fiber population to resistance training in T1DM.  
 Similarly, although aerobic endurance training is typically associated with increasing 
skeletal muscle mitochondrial content, oxidative enzymes, capillary density and overall oxidative 
capacity, it has also been shown to play a role in muscle hypertrophy and muscle atrophy 
prevention 
229,230,235,236
. Hence, aerobic endurance training may also be a candidate for the 
prevention and treatment of diabetic myopathy in addition to its beneficial effects on insulin 
sensitivity and glycemic control 
237
.  Several studies on healthy humans have shown that 12 
weeks of cycle ergometer endurance training (20-45 mins, 60-80% HRR, 3 sessions per week) is 
capable of inducing both whole-muscle and fiber hypertrophy in young men and older men and 
women 
235,238,239
. In STZ-induced T1DM rodents, 8 weeks of progressive treadmill training (5 
days per week, 30 min – 1.5 hr per day) was found to significantly increase gastrocnemius whole 
muscle weight and fiber size compared to sedentary diabetic animals, and this anti-atrophic 
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effect of endurance exercise was shown to be at least partly due to the downregulation of MuRF-
1 mRNA in diabetic exercised animals 
240
. Further support for the notion of aerobic exercise 
conferring protection from fiber atrophy in T1DM is provided by the finding that PGC-1α, the 
master regulator of mitochondrial biogenesis significantly upregulated in response to endurance 
exercise, appears to also inhibit skeletal muscle atrophy through inhibition of FOXO3which 
activates atrogin-1 and MuRF-1 
236,241
.  Indeed, the fact that glycolytic fibers contain lower levels 
of PGC-1α than oxidative fibers has been proposed as one of the factors which contributes to 
glycolytic fiber susceptibility to fasting and glucocorticoid induced atrophy 
242,243
.With these 
skeletal muscle specific benefits of aerobic endurance training considered alongside the post-
exercise hyperglycemia inducing capacity of anaerobic resistance training, the concept of 
combined exercise training to prevent diabetic myopathy is particularly intriguing. In healthy 
adults, combining resistance and aerobic endurance training elicit improved muscle fiber CSA 
hypertrophy after 5 weeks in the vastus lateralis compared to resistance training alone (17% 
versus 9%) in young men, while other studies in older men have shown no difference in muscle 
hypertrophy (11% ) between the two 
244,245
. Interestingly, 14 weeks of concurrent lower body 
endurance and upper body resistance training in active elderly has been shown to induce similar 
increases (38%) in satellite cell counts in muscle samples from both deltoid and vastus lateralis 
muscle samples, primarily in type II muscle fibers 
135
. As such, investigating the potential 
benefits of combining resistance training with aerobic endurance training in T1DM could 
provide insight into whether these aforementioned training effects are preserved in the diabetic 
milieu and could represent an ideal exercise training modality by reducing the risk of post-
exercise hypoglycemia and improving insulin sensitivity while increasing whole muscle and 
fiber hypertrophy. 
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1.15 Concluding Remarks: 
 
 Diabetic myopathy represents a complication associated with T1DM that warrants further 
research for a number of reasons. The rate of T1DM incidence has been reported to be increasing 
on a global scale, and the greatest increment increases have been observed in children under the 
age of 5 years old 
5,14,27–30
. Since skeletal muscle undergoes significant growth and development 
during childhood and adolescence, the increase in children affected by T1DM at a young age has 
potential to increase the severity of the negative effects of diabetic myopathy, manifesting in 
serious health and functional consequences. Furthermore, in an increasingly aging society, 
sarcopenia or the muscle loss (predominately in glycolytic fibers) associated with old age has 
been shown to be more prevalent in older adults with latent autoimmune diabetes and T2DM 
compared to non-diabetics 
246–249
. Improving our current understanding of how to prevent the 
development or attenuate the progression of diabetic myopathy may prove to be critical in 
maintaining skeletal muscle health across the lifespan of patients with T1DM.  
Independent of the epidemiological relevance of researching diabetic myopathy, the 
current body of literature is subject to some criticism in terms of translational ability to humans 
with T1DM. The STZ-induced T1DM rodent model that has been used for the majority of 
diabetic myopathy studies to date presents a few challenges in terms of experimental design that 
make it difficult to compare to humans with T1DM. Firstly, the majority of STZ T1DM rodent 
studies have utilized single high-dose injections of STZ in order to induce diabetes, usually 
between 60-70 mg/kg in rats and 120-250 mg/kg in mice 
157,166,169,180,250–258
. As high doses of 
STZ (100 mg/kg – 150 mg/kg) injected in rats has been found to result in premature death, and 
STZ both in vivo and in vitro has been shown to have deleterious effects on skeletal muscle 
independent of hypoinsulinemia-hyperglycemia in a dose dependent manner, attempts to reduce 
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the myotoxic role of STZ per se on skeletal muscle should be a priority in STZ T1DM models 
investigating diabetic myopathy 
172,173
. A second issue with STZ T1DM models of diabetic 
myopathy is that the majority of these aforementioned studies do not include insulin therapy in 
their experimental design, general resulting in a severe diabetic state. Insulin therapy is 
foundational to the management of T1DM in humans, and a near absence of circulating insulin in 
rodent models of diabetic myopathy limits the degree to which results can be extrapolated to 
humans with T1DM. Moreover, insulin is known to contribute to the maintenance of muscle 
mass primarily through the inhibition of skeletal muscle proteolysis, and even small amounts of 
circulating insulin can significantly inhibit protein breakdown; extreme hypoinsulinemia likely 
exacerbates the diabetic myopathic condition in STZ T1DM models 
259,260
. A consequence of the 
chronic hypoinsulinemia exhibited by STZ T1DM rodents is of course, hyperglycemia, which in 
many rodent models has been reported to be between 20 and 38.8 mmol/l, with some studies 
reporting blood glucose concentrations as high as 44.4 and 56.5 mmol/l 
157,166,168,180,250,252,253,255–
257
. Once again, these extremes in resting blood glucose concentration are unrepresentative of the 
general T1DM population (aside from during the weeks-months prior to diagnosis/insulin 
therapy), and thus detract from the translational capacity of these models. With these limitations 
in mind, one of the aims of the present study was to investigate the role of conventional (blood 
glucose 9-15 mmol/l) compared to intensive (7 – 9 mmol/l) insulin therapy on skeletal muscle in 
multiple low-dose STZ (20 mg/kg) injected T1DM rodents through the use of subcutaneously 
implanted insulin pellets. The blood glucose range for conventional insulin therapy was selected 
in order to provide a comparable level of glycemic control to the general T1DM population, 
whereas intensive insulin therapy represents T1DM patients with tightly controlled blood 
glucose levels 
174,261
. 
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 As exercise is known to produce significant adaptations in skeletal muscle with adaptive 
responses varying in response to specific exercise modality and muscle fiber type, the role of 
exercise training on the skeletal muscle in T1DM specifically also warrants further research 
attention. As previously discussed, resistance, aerobic endurance and combined exercise training 
are particularly interesting potential therapeutic avenues in treating and preventing the 
development of diabetic myopathy, largely due to their beneficial muscle-specific effects. 
However, the majority of studies on exercise training in T1DM have focused primarily on 
improving indices glycemic control rather than examining the effects of exercise modality on 
skeletal muscle and specific muscle fiber populations 
219,223,228,237,262
. Moreover, the few exercise 
training studies that have examined muscle hypertrophy in response to training have either 
utilized extreme experimental conditions such as synergistic ablation to induce chronic overload, 
or have neglected to incorporate insulin therapy and representative blood glucose ranges, 
limiting their translational capacity to humans 
232,253,263
. With consideration of the myriad of 
adaptive responses of skeletal muscle to exercise modality, comparing the effects of different 
exercise modalities within the same model of T1DM could provide insight into how specific 
skeletal muscle fibers adapt despite T1DM. Furthermore, characterizing these differential 
adaptations in T1DM in response to specific exercise modalities could also allow for the 
determination of exercise training protocols designed to optimize the maintenance of skeletal 
muscle mass while conferring improved glycemic control. Hence, the other primary aim of the 
present study was to examine the effects of resistance, aerobic endurance and combined exercise 
training on MHC muscle fibers in a multiple low-dose STZ (20 mg/kg) rodent model of T1DM 
receiving conventional insulin therapy (blood glucose 9-15 mmol/l). The conventional blood 
glucose range in exercise trained animals, in addition to better representing the general T1DM 
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population, was selected in order to also permit comparison of exercised animals with intensively 
treated sedentary animals to identify whether exercise in moderately hyperglycemic conditions is 
comparable or superior to intensive insulin therapy in maintaining/increasing skeletal muscle 
mass. This model of T1DM in which experimental conditions may allow improved translation of 
results to humans in conjunction with submitting animals within the same model of T1DM to a 
range of exercise modalities should produce novel insights into the diabetic myopathy and its 
treatment. 
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CHAPTER 2 
2.1 Introduction: 
 
 Type 1 diabetes mellitus (T1DM) is a condition in which a selective destruction of the 
insulin producing β-cells of the pancreas results in a loss of insulin production, necessitating 
treatment with exogenous insulin in order to control blood glucose levels. The loss of the 
pulsatile insulin response that typically counters increases in blood glucose results in chronically 
elevated blood glucose, or hyperglycemia, which ultimately leads to microvascular, 
macrovascular and neurological complications 
1,2
.  Over time, these complications eventually 
manifest in the form of retinopathy, nephropathy, neuropathy, atherosclerotic cardiovascular and 
cerebrovascular disease  
3
. A less studied complication associated with T1DM is diabetic 
myopathy, where the skeletal muscle of individuals with T1DM typically exhibit lower muscle 
mass, weakness, reduced regenerative and physical capacity as well as a number of hormonal, 
metabolic and histopathological alterations 
4–12
. Another common finding in T1DM is that 
glycolytic muscle fibers (MHC IIb, MHC IIx) appear to be more prone to the atrophic effects of 
the diabetic milieu compared to oxidative muscle fibers (MHC I, MHC IIa), and often exhibit a 
reduced cross-sectional area (CSA) as well as altered metabolic, ultrastructural and regenerative 
properties 
13–24
. Muscle fiber atrophy as well as morphological and ultrastructural abnormalities 
have also been observed in recent onset diabetes in humans prior to the administration of insulin 
and independent of indications of neuropathy 
11,25,26
.  The effects of diabetes mellitus on the 
skeletal muscle of rodents has also been studied extensively,  where induction of T1DM has been 
primarily achieved through the use of streptozotocin (STZ), a glucosamine-nitrosurea compound 
that acts as a powerful alkylating agent methylating the DNA of β-cells resulting in DNA-strand 
breaks, cell death and in-turn a loss of insulin production 
18,27–30
. However, the use of STZ to 
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induce T1DM in rodent models of diabetic myopathy is somewhat problematic, as STZ has been 
shown to have deleterious effects on muscle mass and muscle fiber size independent of 
hypoinsulinemia/hyperglycemia in vivo, and has been shown to impair myoblast proliferation in 
a dose-dependent manner in vitro 
27
. Moreover, the vast majority of STZ-induced T1DM rodent 
models to date have utilized a single, high dose (60-70 mg/kg in rats, 120-250 mg/kg in mice) 
STZ injection protocol, raising concerns about the myotoxic role of STZ per se, in addition to the 
diabetic milieu in the severity of diabetic myopathy progression 
13,14,16–19,21,31–35
. Furthermore, 
the majority of STZ-induced T1DM studies investigating diabetic myopathy have not included 
insulin therapy in their experimental design, resulting in hypoinsulinemic/hyperglycemic 
extremes that are generally poor representations of the human T1DM population 
2,36
. Aside from 
the likely mortal consequences that extremely low insulin/high blood glucose levels would hold 
in humans with T1DM, both hypoinsulinemia and hyperglycemia have independently been 
shown to negatively regulate muscle mass, and as such the severity of these factors may limit the 
applicability of results from previous rodent models to T1DM patients 
11,15,37–40
.  
Skeletal muscle serves as the body’s primary glucose sink and occupies a central role in 
insulin sensitivity. Considering that T1DM predominately arises during adolescence, a period of 
significant muscle growth and development,  it is important to  prevent or treat the progression of 
diabetic myopathy at an early age 
8,11
.  Engaging in physical exercise, which is known to induce 
profound and varied training adaptations in skeletal muscle, has been proposed as a therapeutic 
strategy in the amelioration of the deleterious effects of diabetic myopathy 
41,42
. However, the 
majority of studies investigating the role of exercise (resistance and aerobic endurance) in 
humans with T1DM to date have focused primarily on the role of exercise in maintaining healthy 
blood glucose levels (i.e. glycated hemoglobin or HbA1C), typically with the aim of preventing 
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the development of cardiovascular disease and related complications 
43–47
. Yet, focusing on 
increasing muscle mass in patients with T1DM may afford benefits that extend beyond 
improving functional capacity and muscle quality across the lifespan; as skeletal muscle is highly 
metabolically active, increased muscle mass may improve insulin sensitivity and glycemic 
control. Previous  rodent studies have specifically investigated whole-muscle and muscle fiber 
hypertrophic capacity in T1DM through the use of synergistic ablation and progressive overload 
resistance training protocols 
31,33,48,49
. While these studies have found that skeletal muscle 
maintains a capacity for hypertrophy despite T1DM, the drastic nature of synergistic ablation 
induced chronic overload is difficult to compare with the training effects of whole-body 
voluntary exercise. Moreover, these studies do not address the muscle fiber-type specific effects 
of T1DM or overload in terms of MHC isoforms, considered the best available marker for fiber 
type, which is likely necessary to fully understand the fiber-type specific nature of training 
adaptations in T1DM 
50
. 
   Aerobic endurance training has typically been associated with increases in indices of 
oxidative capacity in the skeletal muscle of humans and rodents (i.e. increased mitochondrial 
content, oxidative enzymes and capillarization), however, some research has indicated that 
aerobic training alone or in conjunction with resistance training can  be advantageous in terms of 
conferring muscle and fiber hypertrophy as well as preventing T1DM induced muscle atrophy 
42,51–56
.Indeed, in human subjects it has been reported that  performing a combination aerobic 
endurance and resistance training results in greater increases in muscle fiber CSA compared to 
resistance training alone 
54,55
. Conversely, higher intensity resistance exercise may mitigate the 
potential for hypoglycemia that is often observed after aerobic endurance training 
44,57,58
.  As 
such, characterizing the effects of different modalities of exercise (resistance, aerobic endurance 
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and combined) on MHC muscle fiber size is important in order to understand how specific 
muscle fiber-types respond to different types of exercise in T1DM. The aim of the present study 
was to investigate the role of insulin therapy and exercise modality in maintaining or increasing 
muscle fiber CSA in a multiple low-dose STZ, insulin-treated rodent model of T1DM. Firstly, 
we hypothesized that intensive insulin therapy (blood glucose 7-9 mmol//l) would result in 
superior maintenance of muscle fiber CSA compared to conventional therapy (9-15 mmol/l) in 
sedentary animals. Secondly, we hypothesized that exercised animals (resistance, aerobic 
endurance or combined) receiving conventional insulin therapy (9-15 mmol/l) would display 
increased muscle fiber CSA compared to control and sedentary diabetic animals despite 
moderate hyperglycemia, and that animals subjected to resistance/combined training would 
display the greatest increases in fiber CSA.  
2.2 Materials and Methods: 
 
Ethics approval 
The protocols used in the present study were approved by the University Council of 
Animal Care of Western University (London, Ontario, Canada) in accordance with the standards 
of the Canadian Council on Animal Care (APPENDIX B) 
Animals 
Thirty-six, 8 week old, male Sprague-Dawley rats were obtained from Charles River 
Laboratories (St. Constant, Quebec, Canada). All rats were caged in pairs and held on a constant 
12 hour dark/light cycle, temperature (20 ± 1°C) and relative humidity (50%) for the duration of 
the study. All rats were allowed access to standard rat chow and water ad libitum. 
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Experimental groups 
 The rats were randomly assigned to one of six treatment groups. The resulting groups 
were as follows:  control sedentary (CS; n=6), diabetic conventional therapy (DCT; n=7), 
diabetic intensive therapy (DIT; n=7), diabetic resistance exercise (DRE; n=7), diabetic high 
intensity aerobic exercise (DHE; n=5) and diabetic combined exercise (DCE; n=4). Although all 
diabetic groups began with a similar number of animals, severe freeze artifact in some plantaris 
muscle samples resulted in the reduced number of animals in DHE and DCE groups.  
Experimental Procedures 
Diabetes Induction and Insulin Pellet Implantation 
 After a 5 day acclimatization period following arrival, T1DM was induced in rats through 
the use of intraperitoneal (IP), low-dose streptozotocin 20mg/kg (STZ; Sigma-Aldrich) injections 
over 5 consecutive days 
36,59,60
. All STZ injections were dissolved in a 0.1 M citrate buffer (pH 
4.5) and performed within five minutes of preparation. The development of T1DM was 
confirmed by measures of non-fasted blood glucose (BG) of ≥ 18 mmol/L on two consecutive 
days. If necessary, subsequent injections were performed until diabetes was confirmed 
(APPENDIX A1). Following confirmation of diabetes, insulin therapy was provided through 
surgical implantation of abdominal-subcutaneous insulin pellets (1 pellet; 2U insulin/day; 
Linplant, Linshin) (APPENDIX A2). Hyperglycemic range was controlled through adjustment 
(addition or removal ±0.5 pellet) of insulin pellets; DCT rats were adjusted to maintain a BG 
range of 9-15 mmol/L while DIT rats maintained a BG range of 7-9 mmol/L.  
Exercise Training Protocols 
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 The resistance training protocol used was adapted from Hornerberger and Farrar, and has 
been implemented previously in our lab to simulate resistance exercise parameters and 
physiological adaptations observed in resistance training in humans 
59,61
. Following confirmation 
of diabetes and insulin pellet implantation, rats were required to climb a ladder (1.1m, 80°) with 
weight secured to the proximal portion of the tail contained in a small fabric bag. Familiarization 
involved a total of 10 ladder climbs, with progressive increases in weight up to 35% body mass 
for 5 days. Following each climb rats were allowed to rest in a dark box on top of the climbing 
apparatus for ~2min. Pre-training maximal carrying capacity was determined by initial loading 
of 75% body mass, with each subsequent climb adding 30g of weight until animals were unable 
to successfully complete the climb. Resistance training took place 5 days per week for 12 weeks. 
During training sessions rats were loaded with 50%, 75%, 90% and 100% of pre-determined 
maximal carrying capacity performing single climbs, and then completed climbs at 100% until 
exhaustion or unwillingness to climb despite pressurized air/tactile stimulation of the haunches. 
New maximal carrying capacity was determined every 3 days.  
 The high-intensity aerobic exercise protocol was one used by our lab to elicit levels of 
70-80% of VO2max 
59,60,62
. Following diabetes confirmation and insulin pellet implantation, rats 
were familiarized for 5 days by running for 15 mins on a motorized treadmill by running at 
progressively higher speeds up to 30 m/min, 0° grade. Following familiarization, high-intensity 
aerobic training involved running for 1 hour at 27 m/min on a 6% gradient, 5 days per week for 
12 weeks and motivated to run through the use of pressurized air/tactile stimulation of the 
haunches. Combined exercise training involved alternating the aforementioned resistance and 
high-intensity aerobic exercise training protocols 5 days per week for 12 weeks, where resistance 
training would be performed 3 times one week (high-intensity aerobic exercise 2 times) and 
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high-intensity aerobic exercise would be performed 3 times the following week (resistance 
training 2 times).  
Experimental Measures 
Body Weights, Blood Glucose 
 Body weights (BW) were measured and recorded on a weekly basis throughout the 
course of the study. Blood glucose (BG) measurements were made weekly by collecting a blood 
droplet (~50 µL) from the manually occluded saphenous vein, and analyzed via the Freestyle 
Lite Blood Glucose Monitoring System (Abbot Diabetes Care, Inc.). The corresponding BG 
concentration was reported in millimoles per liter (mmol/L).  
Tissue Collection, Immunohistochemistry 
 Rats were sacrificed 72 hours after the last training session by anaesthetization with 
isoflurane followed by cardiac exsanguination. The lower limbs were dissected and the plantaris 
muscles were removed and wet weight recorded. Plantaris muscles were then mounted in 
Cryomatrix
TM
 embedding medium (Lot No. 225229, Thermo Fisher Scientific) and rapidly 
frozen in isopentane cooled to -70°C by liquid nitrogen. Serial 10µm-thick cryosections were cut 
at -20°C with a Leica CM350 Cryostat (Leica Biosystems) and adhered to VWR Superfrost
® 
Plus Microslides (Cat. No. 48311-703, VWR International). All sections were stored at -30°C 
until immunohistochemical analysis.  
 The immunohistochemical methods used were adapted from previously established 
protocols 
63,64
. Prior to staining, sections were allowed to come to room temperature in a 
humidity chamber for ~10 mins. Slides were then washed (5 mins in Tween-PBS, followed by 2 
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x 5 mins in PBS) and then incubated in 3% H2O2 for 15 mins at room temperature to quench 
endogenous peroxidases. Slides were washed again (Tween-PBS 5 mins, PBS 5 mins) and then 
blocked in either 10% (v/v) horse serum with 1% BSA (w/v) in Tween-PBS + Avidin D (Vector 
Laboratories, Inc.) (BS-1), or 10% (v/v) goat serum with 1% BSA (w/v) in Tween-PBS + 
Avidin-D (BS-2) depending on the primary antibody to be applied (Table). After blocking for 1 
hour at room temperature, excess blocking solution was removed from slides and the appropriate 
anti-myosin heavy chain primary antibody dilutions in 1% BS-1 or BS-2 and Biotin (Vector 
Laboratories, Inc.) of BA-D5, SC-71, 6H1 and BF-F3 were applied to detect MHC I, IIa, IIx and 
IIb, respectively (Table 2.1)(Plate 2.1). Slides were then incubated overnight at 4°C. The 
monoclonal antibodies BA-D5 and SC-71 were generously donated by C. Putman, while 
monoclonal antibodies BF-F3 and 6H1 developed by S. Schiaffino and C. Lucas, respectively, 
were obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the 
NIH and maintained at the University of Iowa, Department of Biology (Iowa City, IA, 52242).  
The following day slides were washed again (Tween-PBS 5mins, PBS 5 mins) and secondary 
antibody diluted in appropriate blocking solution were applied (Table 2.1). After 1 hour of 
incubation at room temperature, slides were washed again (Tween-PBS 5 mins, PBS 5 mins) and 
subsequently incubated for 45 mins at room temperature in ABC Peroxidase Staining Kit 
solution (Thermo Scientific). Following another wash (Tween-PBS 5 mins, PBS 5 mins) slides 
were then developed for 6-8 mins in 3,3’-diaminobenzidine (DAB) (Vector Laboratories, Inc.), 
washed in distilled water, dehydrated through graded ethanol washes, and finally cleared with 
xylene. Slide coverslips were adhered with toluene-based mounting resin (Krysalon
™  
Harleco, 
EM Science).  
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Primary 
Antibody 
Blocking 
Solution 
Dilution Secondary 
Antibody  
Dilution  
BA-D5 (MHCI) BS-1 1:20 biotinylated 
horse-anti-mouse 
IgG (H+L) 
1:200 
SC-71(MHCIIa) BS-2 1:10 biotinylated 
goat-anti-mouse 
IgG (H+L) 
1:200 
6H1(MHCIIx) BS-2 1:10 biotinylated 
goat-anti-mouse 
IgG (H+L) 
1:200 
BF-F3(MHCIIb) BS-1 1:100 biotinylated 
horse-anti-mouse 
IgG (H+L) 
1:400 
 
Table 2.1: Primary antibody dilutions, blocking solution, and secondary antibody dilution. BS-1, 
BS-2 = blocking solution made with horse and goat serum, respectively. 
 The antigen specificity of the primary antibodies used was confirmed by the use of an 
adjusted metachromatic dye-based myosin ATPase stain originally developed by Ogilvie et al. 
and adapted for use in rat muscle by Walsh et al. 
65,66
. The method consisted of an 8 min 
incubation in an acidic (pH 4.4) pre-incubation solution, followed by three 2 min washes in Tris 
buffer (pH 7.8). Slides were then incubated for 30 mins in an ATP-incubation solution (pH 9.4), 
dipped 4 times in three changes of 1% calcium chloride dihydrate solution and allowed to 
incubate for 90s in a 0.1% toluidine blue solution. Slides were then promptly rinsed in running 
ddH2O for 30s, and rapidly dehydrated by 5 dips in 95% ethanol, two sets of 5 dips in 100% 
ethanol, and 1 min in xylene. Slide coverslips were adhered with toluene-based mounting resin 
(Krysalon
™  
Harleco, EM Science). (Plate 2.1) 
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Microscopy Image Collection and Muscle Fiber Cross-Sectional Area Analysis 
All microscopic imaging was performed on a Zeiss Axio Vert.A1 microscope equipped 
with an AxioCam ICc 5 camera, linked to the Zen 2.3 Lite computer-based image analysis 
program (Carl Zeiss AG). Five distinct regions on each section were captured at 10x 
magnification; care was taken to ensure that the same five regions were captured on each of the 
MHC stains per animal. Regions were chosen to represent all quadrants and central area of the 
muscle. 
Muscle fiber cross-sectional areas were measured using Adobe Photoshop® CC (Adobe 
Systems). Scale was determined through the use of a 25mm stage micrometer (KR-814) and the 
“set measurement scale” option to convert area in pixels to microns squared (μm2). The “quick 
selection” tool was then used to record the cross sectional areas of individual muscle fibers and 
exported from the “measurement log” as a delimited text file to Microsoft Excel.  
Data Analysis  
 Body weight, blood glucose, plantaris wet weight, and muscle fiber cross-sectional areas 
within and between groups were compared using a one-way analysis of variance (ANOVA) with 
GraphPad Prism 5 (GraphPad Software, Inc.). On determination of significant differences, 
pairwise post-hoc analysis was performed using the Tukey test. Differences were considered 
significant at P<0.05. Fiber CSA frequency distributions were generated with GraphPad Prism 5 
by taking frequency distribution values for number of fibers per bin size and dividing that 
number of fibers by the total fiber number for that specific MHC and group, resulting in 
frequency distribution of fiber size expressed as a fractional percentage (i.e. 0.3 = 30%) of total 
fiber population.  
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2.3 Results: 
 
Physical Characteristics: 
Physical characteristics (terminal body weight (g), plantaris whole-muscle weight (mg) 
and terminal blood glucose (mmol/l) are presented in Table 2.2. Terminal body weights of all 
groups except were similar, except for DIT which was significantly greater than DRE (P< 0.05). 
Plantaris whole-muscle weights were not significantly different between any treatment groups 
(P>0.05). Although frequent adjustments to the number of implanted insulin pellets were made 
over the course of the study in an effort to maintain conventional (9-15mmol/l) and intensive (7-
9mmol/l) blood glucose ranges as closely as possible, terminal blood glucose concentration was 
not different between diabetic groups (DCT, DIT, DRE, DHE, DCE), and CS terminal blood 
glucose was significantly lower than all diabetic groups (P<0.05). It should be noted that 
terminal blood glucose concentrations were determined on unfasted animals. That combined with 
the variability in blood glucose range over the conventional and intensive conditions may have 
led to the lack of differences.  
Resistance Training Load: 
 Resistance training load over the course of 12 weeks of training for both DRE and DCE 
animals is presented in Figure 2.1. Both groups demonstrated significant and near linear 
increases in weight carried over the training period.  
Fiber Type Percent Composition, Cross-Sectional Area and Cross-Sectional Area Frequency 
Distribution: 
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 Myosin heavy chain fiber type percent composition and mean CSA +- SD, as well as 
percent area occupied by the heterogeneous fiber population are presented in Table 2.3.Between 
groups, DRE, DHE and DCE MHCIIa/IIx fiber percent composition was significantly greater 
than DIT animals (P<0.05). CS and DIT groups displayed significantly greater percent 
composition of MHCIIx compared to DCE animals (P<0.05). CS, DCT and DCE animals 
display significantly greater MHCIIx/IIb percent composition than DIT animals (p<0.05). In 
Figure 2.2, mean fiber CSA +- SE differences are presented within experimental treatment 
groups. Within all groups, a general trend of increasing mean fiber CSA occurred from smaller 
oxidative fibers to larger glycolytic fibers, and in all groups the mean CSA of MHCIIb fibers 
was significantly greater than all fiber types. 
  Comparisons of mean fiber CSA +- SE between groups and specific fiber type CSA 
frequency distributions are presented in Figures 2.3-2.9. CS MHCIIx/IIb fibers were significantly 
larger than DCT MHCIIx/IIb fibers (P<0.05). DIT animals exhibited MHCIIa and IIa/IIx CSA’s 
that were significantly larger than all other treatment groups (P<0.05), MHCIIx CSA that was 
greater (P<0.05) than CS, DCT and DHE, and MHC IIx/IIb as well as MHCIIb CSA’s that were 
greater (P<0.05) than CS and DCT animals. DRE animals displayed MHCIIa CSA that was 
greater (P<0.05) than DHE, MHCIIa/IIx that was greater (P<0.05) than CS, DCT and DHE, 
MHCIIx CSA that was greater (P<0.05) than CS, DCT, DIT and DHE groups, as well as 
MHCIIx/IIb and MHCIIb CSA’s that were greater (P<0.05) than CS and DCT treatment groups. 
DHE animals exhibited MHCIIx/IIb fiber CSA that was greater (P<0.05) than DCT and MHCIIb 
CSA that was greater (P<0.05) than CS and DCT treatment groups. DCE animals displayed 
MHCI/IIa CSA that was greater (P<0.05) than CS, DCT and DIT animals, although these fibers 
were very few in number. DCE animals also exhibited MHCIIa CSA that was greater (P<0.05) 
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than DCT and DHE, MHCIIa/IIx CSA greater (P<0.05) than CS, DCT and DHE, MHCIIx CSA 
greater (P<0.05) than CS, DCT and DHE, MHCIIx/IIb CSA greater (P<0.05) than CS and DCT 
and MHCIIb CSA that was significantly larger (P<0.05) than all other treatment groups.  
 
 
Group CS (n=6) DCT (n=7) DIT (n=7) DRE (n=7) DHE (n=5) DCE (n=4) 
Terminal 
BW (g) 
613.0 ± 
83.2 
560.0 ± 
69.7 
621.1* ± 
45.8 
519.7 ± 
56.1 
513.2 ± 
51.6 
536.5 ± 
54.6 
Plantaris  
Wt. (mg) 
547. 9 ± 
72.7 
546.5 ± 
88.3 
609.6 ± 
73.5 
521.6 ± 
47.3 
570.7 ± 
55.8 
522.3 ± 
55.1 
Terminal  
BG 
(mmol/l) 
3.983** ± 
0.3 
16.43 ±  
1.9 
11.81 ±  
3.6 
12.40 ±  
5.2 
15.54 ±  
1.3 
16.93 ±  
2.1 
 
Table 2.2: Physical characteristics for experimental treatment groups. All data presented as 
mean ± SD. *=sig. > DRE. ** = sig. < all other groups. 
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Figure 2.1: Mean maximal resistance training load for DRE and DCE groups over course of 12 
weeks of training. All data points expressed as mean ± SE. 
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Condition  MHCI MHCI 
/IIa 
MHCIIa MHCIIa 
/IIx 
MHCIIx MHCIIx 
/IIb 
MHCIIb %  
Hybrid 
          
CS # 267 16 610 267 1004 501 569  
n = 3234 % 8.26 0.49 18.86 8.26 31.04 15.49 17.59 24.24 
 cross 2757 
±830.4 
2215 
±581.7 
2439 
±687.6 
2784 
± 831.6 
3306 
±888.7 
4216 
±1264 
4489 
±1190 
 
 % 
area 
6.78 0.3 13.5 6.96 29.46 18.52 24.47 25.78 
          
DC # 258 39 566 172 798 424 759  
n = 3016 % 8.55 1.29 18.77 5.7 26.46 14.06 25.17 21.05 
 cross 2930 
±893.6 
2211 
±636.2 
2420 
±759.1 
2907 
±705.1 
3340 
±997.5 
3740 
±1044 
4330 
±1263 
 
 % 
area 
7.48 0.87 13.44 4.90 26.16 15.56 32.30 21.33 
          
DIT # 306 15 788 33 879 104 763  
n = 2888 % 10.6 0.52 27.28 1.14 30.44 3.60 26.42 4.26 
 cross 2889 
±1161 
2201  
±572.2 
2792 
±897.5 
4296 
±933.3 
3633 
±1024 
4657 
±1159 
 
5034 
±1606 
 
 % 
area 
8.38 0.3 20.5 1.31 29.54 4.43 35.54 6.04 
          
DRE # 278 66 532 350 780 259 655  
n = 2920 % 9.52 2.26 18.22 11.99 26.71 8.87 22.43 23.12 
 cross 2920 
±1151 
2643 
±817.5 
2540 
±828.9 
3298 
±1229 
3821 
±1257 
4657 
±1491 
5229 
±1420 
 
 % 
area 
7.3 1.57 12.16 10.37 26.82 10.91 30.87 22.85 
          
DHE # 167 13 483 317 413 208 384  
n = 1985 % 8.41 .66 24.33 15.7 20.81 10.48 19.34 26.84 
 cross 2941  
±866.9 
2940 
±638.7 
2325 
±646.9 
2893 
±989.2 
3201 
±1332 
4394 
±1596 
5280 
±1748 
 
 % 
area 
7.24 .56 16.37 13.14 19.35 13.42 29.92 27.12 
          
DCE # 154 32 318 371 192 257 317  
n = 1641 % 9.38 1.95 19.38 22.61 11.7 15.67 19.32 40.23 
 cross 2748  
±703.8 
3117 
±1034 
2574 
±824.9 
3219 
±1158 
3654 
±1136 
4689 
±1655 
6161 
±1481 
 
 % 
area 
6.65 3.03 12.84 18.67 10.93 18.8 30.56 40.5 
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Table 2.3: Total fiber number, percent fiber composition, fiber CSA and percent area occupied 
by fiber population. All fiber CSA values are reported as mean ± SD. 
80 
 
 
A B
C D
E
Myosin ATPase MHCI (BA-D5)
MHCIIa (SC-71) MHCIIx (6H1)
MHCIIb (BF-F3)
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Plate 2.1: Representative images of fiber types in a trained diabetic rat which underwent 
resistance training with I = fibers expressing only MHCI, IIa = fibers expressing only MHCIIa, 
IIx = fibers expressing only MHCIIb, IIB = fibers expressing only MHCIIb.  IIa/IIx and IIx/IIb 
fibers expressing both IIa/IIx MHC’s and IIx/IIb MHC’s respectively.  A) metachromatic myosin 
ATPase. B) BA-D5 antibody specific to MHCI. C) SC-71 antibody specific to MHCIIa. D) 6H1 
antibody specific to MHCIIx. E) BF-F3 antibody specific to MHCIIb. 
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Figure 2.2: MHC fiber CSA differences within groups. All data presented as mean ± SD. 
Differences were considered were considered significant where P<0.05.                                        
* = sig. > MHCIIa, ** = sig. > MHCI/IIa, MHCIIa, *** = sig. > MHCI/IIa, MHCIIa, 
MHCIIa/IIx, α = sig. > MHCI, λ= sig. > MHCIIx, Ω = sig. > all MHC. Exceptions where DIT 
MHCIIa is only sig. > MHCI/IIa, DHE MHCIIx only sig. > MHC IIa, MHC IIa/IIx and DCE 
where MHCIIx only sig. > MHCI, MHCIIa and MHCIIa/IIx. 
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Figure 2.3: MHC CSA differences between groups and fiber CSA frequency distributions for 
MHCI. A) MHCI CSA differences between groups, data expressed as mean ± SD, no statistically 
significant differences. B – H) Fiber CSA frequency distributions for CS, DCT, DIT, DRE, DHE 
and DCE groups. 
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Figure 2.4: MHC CSA differences between groups and fiber CSA frequency distributions for 
MHCI/IIa A) MHCI/IIa CSA differences between groups, data expressed as mean ± SD. B-H) 
Fiber CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. *** = sig. > 
CS, DCT, DIT. 
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Figure 2.5: MHC CSA differences between groups and fiber CSA frequency distributions for 
MHCIIa A) MHCIIa CSA differences between groups, data expressed as mean ± SD. B-H) Fiber 
CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. * = sig.> DCT, λ= 
sig. > DHE, Ω = sig. > all groups.  
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Figure 2.6: MHC CSA differences between groups and fiber CSA frequency distributions for 
MHCIIa/IIx A) MHCIIa/IIx CSA differences between groups, data expressed as mean ± SD. B-
H) Fiber CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. ** = sig. 
> CS, DCT, λ= sig. > DHE, Ω = sig. > all groups. 
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Figure 2.7: MHC CSA differences between groups and fiber CSA frequency distributions for 
MHCIIx A) MHCIIx CSA differences between groups, data expressed as mean ± SD. B-H) Fiber 
CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. ** = sig. > CS, 
DCT, *** = sig. > CS, DCT, DIT, λ= sig. > DHE 
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Figure 2.8: MHC CSA differences between groups and fiber CSA frequency distributions for 
MHCIIx/IIb A) MHCIIx/IIb CSA differences between groups, data expressed as mean ± SD. B-
H) Fiber CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. * = sig.> 
DCT, ** = sig. > CS, DCT. 
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Figure 2.9: MHC CSA differences between groups and fiber CSA frequency distributions for 
MHCIIb A) MHCIIb CSA differences between groups, data expressed as mean ± SD. B-H) Fiber 
CSA frequency distributions for CS, DCT, DIT, DRE, DHE and DCE groups. ** = sig. > CS, 
DCT, Ω = sig. > all groups. 
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2.4 Discussion: 
 
The present study demonstrated that both exercise modality and intensity of insulin 
therapy induce differential effects on the cross-sectional area (CSA) of muscle fibers identified 
by myosin heavy chain in multiple low-dose STZ-diabetic, insulin treated rats. Furthermore, this 
study provided support for the protective effect of both exercise and insulin in the attenuation of 
the reduced body weight, whole-muscle weight and glycolytic muscle fiber size commonly 
observed in diabetic myopathy 
8,11,13,67
.  Although several studies have examined the effects of 
T1DM and STZ-induced T1DM on skeletal muscle in both humans and rodents, there is a 
paucity of research examining the long-term effects of different types of exercise training and 
insulin therapy regimens on the CSA of muscle fibers identified specifically by their MHC 
content. As muscle fibers expressing different MHC display differential sensitivity to various 
atrophic stimuli, analyzing fiber size in the context of each of the four MHC’s (as well as 
“hybrid” fibers co-expressing MHC’s) in the present model of T1DM has allowed for a 
characterization of how these fibers respond to exercise and insulin therapy in a diabetic milieu 
23
.  In addition, studies utilizing STZ to induce the development of T1DM have been considered 
contentious in regards to diabetic myopathy, as often,  the dose of STZ administered has been 
shown to have atrophic and metabolic effects on muscle fibers independent of hyperglycemia 
27,36,68,69
. Hence, a multiple low-dose STZ injection protocol was used to induce T1DM in the 
present study in an attempt to restrict the atrophic effects of STZ per se as opposed to 
hyperglycemia and/or hypoinsulinemia associated with T1DM. Further, like many rodents 
studies of STZ induced T1DM, subcutaneously implanted insulin pellets and specific blood 
glucose range clamps were employed in an attempt to provide a more realistic model of the 
average T1DM human population 
70
. The use of an appropriate insulin supplemented STZ 
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model, reminiscent of human T1DM, largely maintained body mass, and muscle fiber size 
despite chronic, moderate hyperglycemia. All of the exercise models employed in the present 
study appeared, at minimum, to maintain muscle fiber size (aerobic endurance) or result in 
increased fiber CSA (resistance, combined). Exercise did differentially influence both muscle 
fiber composition and fiber size of specific fiber types, however, collectively, the use of multiple 
low-dose STZ induction of T1DM, efforts to control blood glucose in physiologically relevant 
ranges via insulin supplementation, long term exercise training, and IHC identification and 
analysis of MHC specific fiber CSA have afforded novel insights into the muscle fiber specific 
nature of diabetic myopathy.  
A common finding in many STZ induced T1DM rodent models investigating diabetic 
myopathy are physical characteristics including significantly reduced body weight and whole-
muscle weight in diabetic animals compared to non-diabetic controls 
11,14–16,18,20,22,31,34,71
. In the 
present study, the finding that mean terminal body weight and whole-muscle plantaris weight in 
all groups were not significantly different from one another (except for where DRE body weight 
was significantly smaller than DIT) is likely due to a number of different factors including the 
nature of the experimental design (STZ dose, insulin treatment, blood glucose levels), muscle-
specific factors (muscle glycogen and lipid levels, H2O content) and exercise training. Unlike the 
present study, the majority of previous STZ T1DM rodent models reporting significantly reduced 
body and whole-muscle weight in diabetic animals tend to have utilized a single, high-dose STZ 
injection, typically between 60-70 mg/kg in rats and 120-250 mg/kg in mice 
13,14,16,18,21,22,31–34,71–
73
. As previously mentioned, STZ has been shown to exhibit negative effects on skeletal muscle 
growth and development independent of the resultant hyperglycemia and/or hypoinsulinemia that 
follows STZ-induced pancreatic β-cell apoptosis. Johnston et al. examined these muscle-specific 
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effects of STZ in vivo and in vitro using young Sprague-Dawley rats and C2C12 myoblasts, 
respectively and  the changes were determined to be dose-dependent in nature and due to a G2/M 
phase cell cycle arrest  
27
. As the repair of DNA damage primarily occurs during the G2 phase 
prior to entering the M (mitotic) phase of the cell cycle, and STZ treatment is generally 
understood to cause DNA alkylation through an increase of free radicals and ROS, the G2/M 
phase cell cycle arrest observed in vitro was suggested to support the idea that STZ exposure 
induces significant DNA damage in myoblasts 
27
. Hence, the multiple, low-dose STZ (20mg/kg) 
model employed in the present study may have played a role in the relative maintenance of body 
and whole-muscle weight observed treatments by reducing the dose-dependent myotoxic effects 
of STZ in all of all of the experimental treatment groups. It should be noted, however, that STZ 
transportation relies on the presence of the glucose transporter isoform GLUT2, which although 
largely expressed in the liver and pancreas has been shown to be expressed only in small 
quantities in skeletal muscle, and thus may actually indicate a limited capacity of STZ for 
myotoxicity   However, as measured, the terminal body weights of the animals in the present 
experiment did not allow for distinguishing between the relative contributions of lean body mass 
(i.e. muscle) versus fat mass. Body composition analysis would have been helpful in this regard, 
as observation suggested that DIT animals had significantly more abdominal fat (as has been 
observed in intensively treated human subjects) than their exercise trained counterparts. 
Most studies using STZ to assess the effect of T1DM on muscle mass have reported 
reduced whole-muscle weight and a preferential atrophy of glycolytic muscles/fibers. However, 
they have neglected to control blood glucose through insulin supplementation, and as such the 
blood glucose concentrations exhibited by these animals are far greater than would be observed 
in most human patients with T1DM 
36
. Blood glucose concentrations throughout the course of 
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experimentation or at the time of sacrifice, ranged anywhere from 20 mmol/l to 38.8 mmol/l, 
with some studies reporting blood glucose levels as high as 44.4 and 56.5 mmol/l 
13,14,16,18–
21,31,33,34,74
. In the present study, effort to clamp blood glucose ranges (7-9 mmol/l for intensive, 
9-15 mmol/l for conventional therapy and exercised groups ) was used in order to model both the 
tightly regulated/monitored and moderately hyperglycemic conditions that are more 
representative  of the general human population living with T1DM 
36,70
. The disparity between 
blood glucose levels typically observed in humans with T1DM and those reported in rodent 
models of diabetic myopathy is an important consideration as hyperglycemia per se has been 
shown to have deleterious effects on skeletal muscle. Krause et al. have indicated that some of 
the negative outcomes of hyperglycemia related to the diabetic myopathic condition and negative 
regulation of muscle mass likely includes the formation of advanced glycation end products 
(AGE), chronic oxidative stress, and the polyol pathway 
11
. Hypoinsulinemia per se is also a key 
contributor alongside hyperglycemia to diabetic myopathy. Humans and animals with T1DM 
that are not subjected to insulin treatment  develop a catabolic state where the rate of protein 
catabolism exceeds the rate of protein synthesis, and in turn results in a net loss of protein that is 
especially evident in skeletal muscle 
75
.  Hence, the use of intensive and conventional insulin 
therapy treatment for sedentary and exercised diabetic animals in the present study was also 
likely a significant contributor to the maintenance of body and whole-muscle weight as well as 
fiber CSA that was observed in all groups. The effects of insulin treatment on skeletal muscle 
mass in T1DM have been determined to be due primarily to an anti-catabolic effect in the 
reduction of muscle protein breakdown as opposed to an  increase in muscle protein synthesis 
39,76
.  Significant inhibition of muscle protein catabolism can be induced by even minute 
increases in circulating insulin concentration (i.e. to 104.2 pmol/l), whereas increases in insulin 
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within postprandial ranges does not exert an increase in muscle protein synthesis. The important 
role of insulin supplementation in the maintenance of skeletal muscle mass has been 
investigated, the results of which are especially pertinent to the present study. The investigators 
used both low multiple-dose (45 mg/kg x 5 days, IP) and single high-dose (180 mg/kg, IP) STZ 
injections for comparison  
40
.  Mice subjected to multiple-dose STZ exhibited a reduction in body 
weight (13%) and 1.88 fold increase in myostatin (MSTN) compared to controls, while high-
dose mice exhibited a severe reduction in body weight (27%) and a 3.7 fold increase in MSTN, 
likely indicating a role of MSTN expression and severity of muscle atrophy 
40
. As a growth and 
differentiation factor, MSTN is known as a potent negative regulator of muscle mass in humans 
and animals, and MSTN inhibition has been shown to increase muscle mass, fiber size, insulin 
sensitivity, p-Akt expression and GLUT4 expression, improve muscle regeneration and reduce 
atrophy 
77–85
. Of particular significance is that treatment of the multiple-dose STZ animals with 
insulin after 2 weeks of diabetes (4IU/day x 3 days, subcutaneous injection) not only corrected 
hyperglycemia and loss in body weight but completely ameliorated the increased MSTN and 
atrogin-1 expression 
40
. Not only does this suggest that diabetes in the absence of insulin, even 
using a multiple low-dose STZ protocol can significantly reduce body weight and upregulate 
MSTN and atrogin-1; but that insulin treatment can completely “reverse” these atrophic indices. 
Another recent rodent study has suggested the use of MSTN inhibition as an adjuvant therapy in 
treating T1DM, after finding that in addition to prevention of muscle loss, MSTN mRNA 
reduction led to increases in insulin sensitivity as well as increases in GLUT4 expression which 
led to significant improvement in blood glucose regulation 
85
. Hence, it is possible that the 
maintenance of body weight, muscle mass  and fiber CSA may be partially due to the role of 
insulin treatment  in attenuating MSTN expression as well as preventing a net protein catabolism 
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of skeletal muscle from taking place.  
 Insulin treatment in DCT, DIT and exercised animals (DRE, DHE, DCE) was also 
essential for controlling blood glucose levels and thus reducing the negative effects of 
hyperglycemia on skeletal muscle mass. We had hypothesized that intensive insulin therapy 
(blood glucose 7-9 mmol//l) would result in superior maintenance of muscle fiber CSA 
compared to conventional therapy (9-15 mmol/l) in sedentary animals.  We based this upon the 
known effects of hyperglycemia, including an acceleration of the process of glycation resulting 
in the formation of cross-linkages between proteins known as advanced glycation end products 
(AGE) 
86,87
. AGE accumulation in both serum and muscle has been associated with reducing 
motor function and grip strength in non-diabetic elderly individuals 
1,86,88–91
. In T1DM muscle, 
AGE accumulation is most evident in fast fibers which are also the most affected by diabetic 
myopathy 
90,92,93
. In addition, hyperglycemia is also associated with elevated ROS and activation 
of the polyol pathway, both of which may contribute to diabetic myopathy The fact that both  
DCT and DIT were relatively unaffected by differences in hyperglycemia compared to CS 
further suggests that the presence of insulin may override the negative impact of hyperglycemia 
on skeletal muscle, at least in the short term. As expected, intensive insulin therapy permitted the 
same benefits that conventional insulin therapy conferred in maintaining body weight, whole-
muscle weight and fiber CSA compared to healthy controls. However, the present data seem to 
indicate that treatment with an increased dose of insulin may have differential effects on specific 
MHC fiber types in sedentary rodents despite the reported role of insulin only increasing muscle 
protein synthesis in the presence of elevated amino acid levels 
39,76
.  Although maintained or 
improved CSA compared to DCT animals was expected in DIT animals, the observation that 
mean  MHC IIa fiber CSA was significantly larger than all other conditions including exercise 
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was surprising. As food and water were provided ad libitum, it is possible that DIT animals may 
have engaged in hyperphagia, elevating circulating amino acid levels and thus increasing the rate 
of muscle protein synthesis in conjunction with reducing the rate of muscle protein breakdown. 
However, the finding that DIT MHC IIa/IIx fibers are also significantly larger than all other 
conditions and exhibit a frequency distribution that appears somewhat bimodal and is noticeably 
right-shifted seems to indicate that a transition from MHC IIx to IIa is responsible for the robust 
increase in DIT MHC IIa CSA and the slightly higher MHC IIa percent composition. 
Interestingly, DIT animals also exhibited far fewer hybrid fibers than any other group (Table 
2.2). This could indicate that elevated insulin levels “lock in” single phenotype fibers or that any 
fiber type transitions resulting from insulin supplementation are complete by the end of 12 
weeks.  
The present study’s investigation of fiber type percent composition in plantaris also 
provided insight into the fiber specific effects of diabetic myopathy. In general, all groups 
maintained  similar percent composition of specific fiber types as has been previously observed 
in healthy rat plantaris muscle, where slow oxidative (MHCI) fibers occupy ~10% of the fiber 
population and fast oxidative glycolytic and fast glycolytic (MHC IIa, MHCIIx and MHC IIb) 
make up the remaining 90% of the fiber population 
95
.This is in agreement with previous studies 
13,18
. However, both exercise and insulin supplementation appeared to differentially influence 
muscle fiber proportions particularly within the MHCIIx fibers (Table 2.2). The composition of 
the more oxidative MHCI and MHCIIa were largely unaltered by diabetes, with or without 
exercise, probably as a consequence of the presence of insulin and the fact that they are 
frequently recruited. In rodents, resistance training has been shown to result in increases in the 
expression of MHCIIx fibers, whereas aerobic endurance training generally increases the percent 
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composition of MHCIIa and MHCI fibers 
96
. In the present study, all exercise conditions 
exhibited significantly elevated proportions of hybrid IIa/IIx fibers suggesting that both 
resistance and aerobic exercise tended to generate fiber type transitions. In fact, more than 20% 
of muscle fibers assessed in the DCE group were MHCIIa/IIx hybrids and DCE also had 
significantly fewer MHCIIx fibers than CS or DIT. These data suggest that both DHE and DCE 
groups may be driving less aerobic MHCIIx to more aerobic fibers expressing MHCIIa. The 
picture is less clear with the DRE resistance exercise condition but given a high proportion of 
MHCIIa/IIx (over 20%) and the observation of 2 distinct peaks of cross-sectional area in these 
hybrids (Fig 2.6) it also appears that the resistance training employed in the present study may 
also transition MHCIIx to MHCIIa fibers. The DIT group which experienced the greatest insulin 
supplementation in contrast had very few hybrid fibers. As noted above, the reason for this is 
uncertain but may be associated with the degree of insulin supplementation. In CS and DIT 
animals, the relative percent composition of MHCIIx fibers was significantly higher than that of 
DCE animals, MHCIIx/IIb percent composition was significantly higher in CS and DCT animals 
compared to DIT. This is expected in comparison to the exercise conditions due to a reduced 
neural influence of physical activity 
23,96,97
. Furthermore, in humans, increases in the percent 
composition of glycolytic fibers has been observed in the skeletal muscle of men with well-
controlled T1DM 
9,11
. It has been proposed that periodic influxes of glucose in response to 
insulin treatment could result in the expression of glycolytic muscle fiber genes and drive this 
increased relative expression, which may explain the observations in DIT animals due to their 
intensive insulin therapy 
11
.  
The effects of different intensities of insulin therapy and exercise modality on the CSA of 
the heterogeneous fiber population in the present study also provided several interesting insights. 
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Within groups and in agreement with previous research, muscle fibers showed a gradual increase 
in CSA moving from more oxidative fibers to more glycolytic fibers, where MHCIIb fibers had 
the largest CSA of all fiber types 
13,50,95,98
. 
The effects of diabetes and exercise became more apparent when the CSA of different 
fiber types was compared between groups. Fibers expressing MHCI appeared to be unaffected by 
either diabetes or exercise. An expected finding, as MHCI has been consistently reported to be 
resistant to the atrophy induced by T1DM 
11,18,23
.  Surprisingly, diabetes did not result in any loss 
of fiber CSA when compared to control animals. Prior research had suggested that fast-twitch, 
particularly MHCIIx and MHCIIb fibers might be particularly sensitive to diabetes resulting in 
reduced CSA 
8,11,13,15,16,74,99
. The fact that no changes were observed in the present study suggests 
that even a minimum amount of insulin is able to maintain fiber size and reduce atrophy. It was 
hypothesized that intensive insulin therapy (DIT) would provide superior maintenance of fiber 
CSA compared to conventional therapy (DCT). This hypothesis was supported but it was 
surprising that for faster fiber types, DIT CSA were actually greater than both the conventional 
diabetic group (DCT) and the control (CS). This was particularly evident for MHCIIa fibers, 
where the average CSA for DIT fibers was greater than any other group and these animals also 
exhibited some of the largest MHCIIa fibers (Fig 2.5). Although the n is small (33 fibers), an 
examination of MHCIIa/IIx hybrids also reveals higher average fiber sizes for DIT as well as 
two populations of fiber sizes which might suggest that transitions are occurring. As the anabolic 
effects of insulin treatment are known to primarily be limited to attenuating muscle protein 
breakdown, these increases in fiber hypertrophy beyond control and exercised animals is 
somewhat perplexing 
39
. However, as elevated levels of amino acids in conjunction with insulin 
have been shown to increase the rate of muscle protein synthesis, it is possible that DIT animals 
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engaged in hyperphagia, thus driving the increased fiber CSA observed 
39,100
. Perhaps fibers 
expressing MHCIIa are particularly sensitive to insulin, although other studies have reported that 
fibers expressing MHCI to have the greatest insulin responsiveness  
101
.The greatly reduced 
number of hybrid fibers co-expressing MHC’s in DIT animals is another surprising finding, and 
in conjunction with DIT’s effect on CSA warrant further investigation. 
Exercise also induced significant and varied changes in CSA in the heterogeneous fiber 
population of diabetic animals. Overall, DHE animals essentially maintained muscle fiber CSA 
while DRE and DCE animals exhibited significant increases in the CSA of specific glycolytic 
fiber populations. Aerobic endurance exercise has typically been shown to induce increases in 
oxidative fibers in non-diabetic rodents and humans (MHCI, MHCIIa, respectively) and even 
result in MHCI and MHCIIa fiber hypertrophy 
51,53,96
. Although hypertrophy of these fiber types 
was not evident in the present study, the reduced MHCIIa CSA when compared to other exercise 
conditions (Fig 2.5A), coupled with the trend toward higher MHCI/IIa hybrid fiber CSA (Fig 
2.4A) and presence of some large MHCI fibers (Fig 2.3G) suggests that perhaps the intensive 
aerobic exercise of DHE is driving muscle fibers to a more oxidative phenotype. DHE animals 
also displayed an increase in MHCIIb fiber CSA compared to DCT animals which may have 
been due to recruitment of these larger glycolytic fibers during the intense aerobic exercise 
sufficient to induce fiber growth.  
As expected, animals that underwent resistance training displayed pronounced increases 
in the CSA of glycolytic fibers (MHCIIa/IIx – MHCIIb – Figs 2.6-2.9), which is consistent with 
previous research on resistance training induced fiber hypertrophy adaptations 
102
. These 
increases in fiber CSA occurred independently of whole-muscle hypertrophy. However, the lack 
of gross hypertrophy in the plantaris muscle of DRE and DCE rats in the present study is 
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supported by previous research using the same resistance training protocol, where only flexor 
hallucis longus (FHL) muscle showed signs of gross hypertrophy 
61
. Both conditions which 
incorporated resistance training exhibited significantly larger type II fibers, with the exception of 
MHCIIb fibers, compared to DHE. This could be partially a function of the additional load 
placed on these fibers during weight lifting or perhaps the smaller MHCIIa-MHCIIx fibers 
observed in DHE may reflect an adaptation where a reduced diffusion distance is critical 
103,104
.  
These differences were particularly evident in the MHCIIa fiber population as even the largest 
fibers in the DHE tended to exhibit a smaller CSA than in the other conditions (Fig 2.5). An 
examination of the range of CSA for MHCIIx fibers in the conditions which incorporated high 
intensity running (Fig 2.7G and H) reveals three peaks in fiber size. Although speculative, it is 
possible that this is further evidence of muscle fiber type transition. Another interesting 
observation was that the combined exercise group DCE exhibited the largest MHCIIb fibers (Fig 
2.9), despite lifting weight only half as often as DRE. Indeed, as noted above, even the MHCIIb 
fibers in DHE were similar in size to those in DRE. Both DRE and DCE animals carried similar 
and progressively heavier loads over the course of the study. However, it is possible that this 
discrepancy may be due to the fact that DRE animals trained 5 days a week, whereas DCE 
animals alternated between daily aerobic endurance and resistance training. This may have 
permitted greater time for muscle recovery between bouts of resistance training. Previous 
research investigating the effect of “over-training” in resistance trained rats has reported findings 
that support this notion 
105. In that study, rats performed a progressive “jumping” resistance 
training protocol over the course of 12 weeks, increasing from 60% to 85% of body weight 
overload, which was reported to be about 15% greater than recommended for inducing muscle 
hypertrophy 
105
. Resistance training was performed 5 days per week in order to limit recovery 
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time between bouts of exercise. Following 12 weeks of training, exercised rats showed decreased 
body weight and significantly reduced plantaris muscle fiber CSA. The maintenance and 
hypertrophy of muscle fibers in DCE animals seems to indicate that combined exercise training 
may be the superior exercise modality of choice for skeletal muscle benefits in T1DM. Not only 
does exercise potentially increase insulin sensitivity, improving glycemic control - reducing the 
risk of cardiovascular disease, it is possible that when performed concurrently with resistance 
training as in DCE animals endurance training may also increase muscle mass while reducing the 
risk of late onset hypoglycemia 
44–46,59
. It should be noted, however, that as endurance and 
resistance exercise training drive the expression of diverse adaptive gene programs, the concept 
of an “interference effect” whereby combined training results in compromised adaptations has 
been postulated 
42
.In human studies of concurrent exercise training, evidence to support the 
notion of concurrent exercise training having superior effects on muscle fiber size has been 
reported. In one study, 5 weeks of combined resistance and endurance training in humans was 
shown to induce greater increases in vastus lateralis muscle fiber CSA (17% versus 9%) than 
resistance training alone, indicating that combined training does not appear to hinder but may 
actually improve the hypertrophic response of muscle fibers 
54
.  Ultimately, the fiber CSA results 
of the present study indicate that combined exercise training results in the greatest benefit in 
terms of muscle hypertrophy, and that the benefits of exercise of any modality in terms of fiber 
CSA are similar to those observed in intensively treated animals, despite exercised animals 
having moderate hyperglycemia. Furthermore, the varied effects of insulin treatment and 
exercise modality on the size of specific muscle fibers in the heterogeneous fiber population 
observed in the present study warrant further investigation, where identifying the molecular 
mechanisms underlying the myriad of fiber adaptations at present will help to further 
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characterize the means by which these fiber size differences occur.  
2.5 Conclusion: 
 
 The deleterious effects of T1DM on skeletal muscle mass and function, collectively 
termed diabetic myopathy, has been reported to result in a preferential atrophy of glycolytic 
muscle fibers compared to oxidative fibers. As T1DM typically develops during adolescence, a 
time of significant skeletal muscle growth and development, early intervention in preventing or 
treating the development of these negative effects of the diabetic milieu on skeletal muscle may 
prove important in maintaining healthy skeletal muscle mass across the lifespan. However, the 
current body of research regarding diabetic myopathy’s fiber-specific atrophic effects has been 
primarily conducted through the use of rodent models of T1DM that are poorly representative of 
the human T1DM population due to extreme levels of hyperglycemia and/or hypoinsulinemia as 
well as high doses of myotoxic STZ to induce β-cell destruction. Moreover, despite the known 
beneficial effects of exercise on skeletal muscle, few studies have been conducted on the effects 
of exercise on muscle fiber size in T1DM, and fewer still have compared the effects of different 
exercise modalities on the heterogeneous fiber population. The aim of the present study was to 
investigate the effects of conventional insulin therapy (DCT; blood glucose 9-15 mmol/l), which 
is more representative of the general T1DM population, compared to intensive insulin therapy 
(DIT; 7-9mmol/l)  and different long-term exercise training modalities (DRE, DHE, DCE; 
resistance, aerobic endurance and combined, respectively) on the CSA of MHC-specific muscle 
fibers 
36,70
. The findings reported presently have afforded insight into how muscle fibers are 
differentially affected by these conditions while utilizing a model STZ-induced T1DM that 
maintains translational capacity to humans with T1DM through the incorporation of 
subcutaneous insulin pellet treatment and specific blood glucoses ranges. 
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 The maintenance of body weight and whole-muscle weight in diabetic animals (sedentary 
and exercised) compared to non-diabetic, sedentary animals showed that even conventional 
insulin treatment is capable of attenuating the reduced body and muscle weight reported in 
previous models of STZ-induced T1DM. As DCT animals, which received both conventional 
insulin treatment and sedentary lifestyles, did not show significant reductions in these measures, 
it is apparent that even moderate hyperglycemia is insufficient to induce severe reductions in 
body weight and muscle mass with mild insulin treatment. Moreover, DCT animals did not 
exhibit reduced fiber CSA compared to CS animals (except for MHCIIx/IIb fibers), further 
highlighting the utility of insulin treatment in maintaining fiber CSA.The only significant 
difference in body weight observed was between DIT and DRE animals, where DRE body 
weight was significantly lower (P<0.05) than DIT animals; however, as DIT and DRE muscle 
weights did not differ this discrepancy could be due to differences in lean versus fat mass 
accumulation. DIT animals displayed unexpected increases in muscle fiber CSA compared to 
both CS and exercised animals, where MHCIIa and MHCIIa/IIx CSA’s were significantly larger 
than all other groups.  
In accordance with previous research, exercise did not result in gross hypertrophy of 
plantaris muscles, although exercise modality did have significant and varied effects on the 
hypertrophy of specific muscle fiber populations 
61
. In general, DHE animals exhibited 
maintenance of fiber CSA, where DRE and DCE animals displayed specific fiber populations 
with markedly increased CSA’s. Although aerobic endurance training has been shown to be 
sufficient to induce hypertrophy in oxidative fibers (MHCI, MHCIIa), the lack of fiber CSA 
increase relative to sedentary control and diabetic animals in DHE animals seems to indicate that 
the effects of aerobic exercise were limited to protection from atrophy, possibly through 
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increased PGC-1α expression 23,106. As expected, both DRE and DCE groups displayed 
significant but unique differences in glycolytic fiber CSA’s. While DRE and DCE animals 
exhibited increases in MHCIIa, MHCIIa/IIx, MHCII, and MHCIIx/IIb, only DCE MHCIIb CSA 
was significantly greater than all other treatment groups. It is possible that the consecutive nature 
of training in DRE animals, where resistance training was performed 5 days per week, resulted in 
insufficient recovery time and thus inhibited the hypertrophy of MHCIIb fibers. Comparatively, 
DCE animals engaged in alternating aerobic endurance and resistance training, allowing greater 
time for muscle recovery while still carrying similar weight loads during resistance training. As 
these findings seem to indicate that combined exercise training may be superior in terms of 
maintaining muscle mass and increasing muscle fiber size across the spectrum of oxidative and 
glycolytic fibers, further studies investigating combined training in humans with T1DM are 
necessary. In general, further support for the notion of a preferential utilization of combined 
training in T1DM patients may be gleaned from the fact that high intensity anaerobic training 
performed prior to aerobic endurance training has been shown to reduce the risk of post-exercise 
hypoglycemia, which is the primary concern of many T1DM patients engaging in exercise 
45,46,107
. In summary, the present study provided important insights into the nature of diabetic 
myopathy’s fiber specific CSA effects in different insulin therapy regimens and exercise training 
modalities; however, identifying the molecular mechanisms responsible for these differential 
effects should be the subject of future studies in order to better characterize these adaptations or 
identify potential pharmaceutical targets.  
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A1. Streptozotocin Induction 
REVISION DATE: 13/06/2012 
PURPOSE:  
To induce Type I diabetes in rats 
 
MATERIALS:  
Gloves 
 Lab Coat 
 Streptozotocin (STZ) 
 5X Stock Citric Acid/Citrate Buffer 
 - Anhydrous Citric Acid 
 - Sodium Citrate Dihydrate 
 - MilliQ Deionized Water 
 13M HCl  
3 Falcon Tubes  
Sterile Filter 
 
EQUIPMENT:  
Biological Safety Cabinet 
 Weigh Scale 
 pH Meter 
 
PROCEDURE:  
Preparing 5X Citric Acid/Citrate Buffer  
1. For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add: 
 i. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid Monohydrate 
 ii. 23.8g Sodium Citrate Dihydrate (Sigma), Mix into… 
iii. 175mL of MilliQ water 
 The pH should be at 4.6, Add HCl or NaOH to adjust (do not over-shoot pH) 
 2. Once the proper pH is obtained, add MilliQ water until you are close to the 200 ml mark (pH 
will move slightly). If satisfied with the pH, adjust volume in a 250 ml graduated cylinder and 
filter in a 0.2µm filter. 
3. Store at room temperature. This is your 5X stock solution. 
 
Making up Streptozotocin (STZ) for Injection  
**NOTE Animals should be pre-weighed prior to making up STZ to ensure accurate amounts of 
STZ to be prepared. 
 
1. Using pre-made buffer, put 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL of distilled 
water filtered through a 0.2µm syringe filter. Check the pH. This gives you a working 
concentration of 153 mM  
127 
 
 
2. The desired pH is between 4.5-4.7. Under the fume hood, add 1 drop at a time of concentrated 
HCl to the buffer, checking pH in between until desired pH is reached. 
 3. Once pH is reached, add 1 mL distilled water (sterile filtered through a 0.2µm syringe filter as 
before). If pH is below 4.5, restart. 
4. Weigh out an appropriate amount of STZ for the number of animals (see calculations below) 
that will be injected in a 15 minute time frame. 
Ex. Rats will be injected at 20mg/kg, so for 10 animals at an ideal weight of 200g (avg. weight of 
rats to be injected), you will require a minimum of 40mg.  
                                          20mg/kg X 0.2kg = 4mg per animal 
The amount of STZ weighed out should be more than the minimum as some solution will be lost 
in filtering. (4mg (per animal) X 12 rats = 48mg total (0.048g) 
5. Dissolve the STZ into buffer (keeping in mind a comfortable injection volume). Shake to 
dissolve powder (approx. 1min). Sterile filter using a 0.2µm syringe filter. Ex. 48mg STZ ÷ 3 
mL buffer = 16mg/mL solution 4mg ÷ 16mg/mL solution = 0.25mL  
6. STZ is time dependent and must be used within 15 minutes 
 
Injecting and Follow-Up of the Animals  
1. Promptly inject each rat with the solution (intraperitoneal) at a dosage rate of 20mg/mL (in 
this example, 0.25mL). Do not use anymore STZ solution more than 15 minutes after it has been 
dissolved in the sodium citrate buffer.  
2. Dispose of any container having come into contact with the STZ (in either powder or 
dissolved form) into a biohazardous waste receptacle. Dispose of needles into a sharps container. 
 3. Return injected rats to their cage. Record the date of STZ injection and add a biohazard label 
to the cage (leave biohazard label on cage for at least 3 days following the last injection).  
4. Repeat this procedure the following day. 
 5. Check blood glucose daily. Diabetes is achieved with two non-fasting blood glucose readings 
of >18 mmol Diabetes should be achieved after 5-8 injections (i.p. 20mg/kg). 
 
Reference: Low dose STZ induction protocol. Animal Models of Diabetic Complications 
Consortium AMDCC Protocols.200 
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A2. Insulin Pellet Implant 
REVISION DATE: 13/06/2012 
MATERIALS: 
 LinShin LinPlant Insulin Pellet  
Rat anesthetic – Isoflurane 
 Ampicillin 
 Sterile water 
 1ml syringe with 25 g needle  
10% providone-iodine solution 
 gauze (or swab)  
Tissue forceps  
Scalpel handle and blades (or scissors)  
Silk suture 
 Needle drivers 
 
EQUIPMENT: 
Isofluorane Anaesthetic Machine 
Hair clippers  
Heat lamp 
 
Special Safety:  
Must don lab coat and gloves before handling rodents. Any bite or scratch that breaks the skin 
must be thoroughly scrubbed with soap and water (report to Occupational Health and Safety). 
 
PROCEDURE: 
 Pellet implantation (for a rat): 
 1. Anesthetize the animal using the isofluorane machine by placing it in the induction chamber. 
Set isoflurane to 4-5% with an O2 flow rate of 1L/min. Open the stopcock valve so gas reaches 
the chamber. Keep in chamber until the animal is unconscious. 
2. Remove the animal and place its nose in the nose cone, reduce the isofluorane to 3% to 
maintain the plane of anesthesia.  
3. Shave the area where the pellet is to be implanted.  
4. Using gauze (or a swab), apply 10% providone-iodine solution to the skin, followed by 70% 
ethanol, to disinfect the site of insertion.  
5. Hold the skin with forceps and make a subcutaneous incision.  
6. Cleanse a 12g trocar with 10% providone-iodine solution and insert it through the puncture 
site to a depth of at least 2 cm.  
129 
 
 
7. Using forceps, briefly immerse the pellet in 10% providone-iodine solution, rinse with saline 
and insert into the subcutaneous region.  
8. Use 1 pellet for the first 350g of body weight. 
9. Pinch the skin closed after the last pellet is inserted. Place a drop of 10 % providone-iodine 
solution over the opening.  
10. Close the incision by suturing.  
11. Place the animal under a heat lamp and monitor until it recovers from anesthesia.  
12. Record on the cage card that insulin pellets have been implanted. 
 
Pellet removal:  
1. Anesthetize the animal as described above for implantation.  
2. Shave and palpate the area of implantation to locate pellets. Sterilize this area by applying 
10% providone-iodine solution followed by 70% ethanol.  
3. Using a scalpel (or scissors), make an incision through the skin superficial to the location of 
the pellets. 4. Using forceps, remove the pellet. Some connective tissue may need to be cut away 
using scissors. Discard the pellet.  
5. Close the incision by suturing.  
6. Place the animal under a heat lamp and monitor until it recovers from anesthesia.  
7. Record on the cage card that the pellets have been removed. 
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A3. Immunohistochemistry Protocol for Myosin Heavy Chain Isoforms 
Advance Preparation 
1. Serial 10µm-thick plantaris cryosections, adhered to VWR Superfrost® Plus microslides, 
stored at -30°C 
2. Ensure all slides are labelled with group, animal number, and slide identification with 
fine tipped pencil 
3. Prepare blocking solution aliquots in 1.5 mL Eppendorf tubes and store at -30°C until 
use: 
BS-1: 10% (v/v) horse serum + 1% (w/v) BSA (ALB001.50, Bioshop) in Tween-PBS 
(pH 7.4) 
BS-2: 10% (v/v) goat serum + 1% (w/v) BSA (ALB001.50, Bioshop) in Tween-PBS (pH 
7.4) 
4. Ensure adequate supply of the following items and solutions: 
- Corning coverslips (#1, 22 x 55 mm) 
- Krystalon™ Harleco (EM Science) mounting medium  
- 10x PBS Stock: KCl 2.0g 
                          NaCL 80g 
                          Na2HPO4: 11.5g  
                          KH2PO4: 2.0g 
                          Bring to 1L with ddH2O 
                         Adjust pH to 7.4 
- 1 x PBS (re-adjusted to pH 7.4 
- 1 x Tween-PBS: 1 x PBS + 0.5 mL Tween-20 (Fisher Scientific) per 1L, re-adjust pH 
to 7.4 
- 30% H2O2 (Caledon Laboratory Chemicals), stored at -30°C 
- 100% ethanol 
- Xylenes 
- The following Vector Lab products: ImmunEdge hydrophobic barrier pen 
                                                           Avidin-Biotin Blocking Kit (SP-2001) 
                                                         DAB Substrate Kit (SK-4100) 
- ABC Peroxidase Staining Kit (#3202, Thermo Scientific) 
- Primary anti-bodies (see below) 
- Vector biotinylated secondary anti-bodies: horse anti-mouse IgG (H+L) (BA-2000) 
                                                                     goat anti-mouse IgG (H+L) BA-9200)    
5. Dehydration tanks, 150 mL each of: 2 x 70% EtOH, 2 x 95% EtOH, 2 x 100% EtOH, 2 x 
100% xylene 
- Seal tanks with paraffin wax to prevent evaporation 
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6. Determine and record specific slide stain designations 
 
Immunohistochemistry Protocol  
Day 1 
1. Remove slides from freezer. 
2. Cover bottom of humidity chambers with dH20 soaked paper towels – place slides on 
racks so that edges hang overhang slightly. Allow slides to reach RT in humidity 
chambers for ~10 min. 
3. Double circle sections with ImmEdge hydrophobic barrier pen. 
4. Wash 1 x 5 min in Tween-PBS, 2 x 5 mins PBS. 
5. Incubate in 3% H202 for 1 x 15 min at RT. 
6. Wash 1 x 10 min in Tween-PBS, 1 x 5 min min in PBS. 
7. Prepare the blocking solution/Avidin mixture by adding 4 drops of Avidin D to each ml 
of blocking solution (BS-1 or BS-2). Approx. 60 µl are required for each section. 
Incubate for 1 hr at RT. Thaw primary antibodies on ice.  
8. Knock off excess blocking solution.  
9. Apply approx. 60 µL of dilute primary antibody which has been diluted in the appropriate 
blocking solution/Biotin mixture (4d Biotin per ml of blocking solution) per section. 
Cover control sections with blocking solution/Biotin mixture without primary antibody. 
Cover humidity chamber and incubate at 4°C overnight.  
Primary 
Antibody 
Blocking 
Solution 
Dilution Secondary 
Antibody  
Dilution  
BA-D5  BS-1 1:20 biotinylated 
horse-anti-mouse 
IgG (H+L) 
1:200 
SC-71 BS-2 1:10 biotinylated 
horse-anti-mouse 
IgG (H+L) 
1:200 
6H1 BS-2 1:10 biotinylated 
goat-anti-mouse 
IgG (H+L) 
1:200 
BF-F3 BS-1 1:100 biotinylated 
goat-anti-mouse 
IgG (H+L) 
1:400 
 
Day 2 
1. Wash 1 x 5 mins Tween-PBS, 1 x 5 mins PBS. 
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2. Prepare appropriate biotinylated 2° antibody at 1:400 or 1:200 in the corresponding 
species blocking solution (BS-1 or BS-2).  
3. Apply 60 µL of biotinylated 2° Ab per section, and incubate 60 for 1 hour at RT. 
4. Prepare ABC Peroxidase Staining Kit: ex. 2 drops of reagent A + 2 drops of reagent B to 
10 mL of PBS. Allow to stand for 30 min at RT before use.   
5. Wash 1 x 5 mins Tween-PBs, 1 x 5 mins PBS. 
6. Apply 60 µL of ABC Peroxidase Stain solution and incubate for 45 min at RT. 
7. Wash 1 x 5 mins Tween-PBS, 1 x 5 mins PBS. 
8. Prepare DAB substrate: to each 2.5 ml of dH20 add 
- 1 drop of buffer stock 
- 2 drops of DAB stock and mix well 
- 1 drop of H202 stock and mix well 
- 1 drop of Nickel stock and mix well 
** 1 drop = ~ 50 µL** 
9. Apply ample substrate solution (DAB/NiCl2) to each section and incubate for 6-8 min at 
RT.  
10. Rinse in dH20 to stop the reaction, place slides in in carriage.  
11. Dehydrate rapidly: 3 mins in 70% ethanol, 1 min in 95% ethanol x 2, 1 min in 100%. 
ethanol; clear in 100% xylene for 1 min.  
12.  Adhere coverslips with mounting medium.  
13. Dispose of excess DAB/NiCl2 solution in designated DAB waste bottle. 
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A4. Metachromatic Dye Myosin ATPase Histochemical Stain 
Advance Preparation: 
1. Acidic pre-incubation solution: 0.49% KCH3COO (w/v) 
                                                   0.26% CaCl2·2H2O (w/v) 
                                                  - adjust pH to 4.4 with glacial acetic acid immediately 
                                                     prior to use                                                            
      2.  0.1 Tris buffer: 12.10g Trizma base 
                                    2.60g CaCl2·2H2O 
                                    -makes 1L, bring pH to 7.8 
3. 1% Calcium Chloride Dihydrate Solution: 10g CaCl2·2H2O  
                                                                        -add to 1L ddH2O 
4. 0.1% toluidine blue solution: 0.1% toluidine blue (w/v) for desired volume  
                                                   - ex. 50 mL of solution = 50 mg toluidine blue, mix well 
5. 150 mL each of 95% ethanol, 2 x 100% ethanol, 1 x 100% xylene  
6. ATP Incubation solution: 0.4% glycine (w/v) 
                                              0.42% CaCl2·2H2O (w/v) 
                                              0.32% NaCl (w/v) 
                                               0.19% NaOH (w/v) 
                                               0.3% ATP (w/v) 
                                              -adjust pH to 9.4 with 5N HCl immediately prior to use 
                                              - prepare this solution immediately prior to staining 
Staining Protocol: 
1) Incubate 8 mins at RT in pre-incubation solution 
2) Wash 3 x 2 mins in Tris buffer 
3) Incubate 30 mins at RT in incubation solution 
4) 4 dips x 3 changes in CaCl2 2H2O solution 
5) Incubate 90s in 0.1% toluidine blue solution 
6) Rinse in running ddH2O for 30s (max.)  
7) Dip 5 x in 95% ethanol, 5 times in 2 changes of 100% ethanol, incubate 1 min in xylene 
8) Mount with toluene based mounting medium 
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